

Synthesis of Imidazolidin-2-ones and Imidazol-2-ones via Base-Catalyzed Intramolecular Hydroamidation of Propargylic Ureas under Ambient Conditions

Alessandra Casnati,[†] Antonio Perrone,[†] Paolo P. Mazzeo,^{†,‡} Alessia Bacchi,^{†,‡} Raffaella Mancuso,[§] Bartolo Gabriele,[§] Raimondo Maggi,[†] Giovanni Maestri,[†] Elena Motti,[†] András Stirling,^{*,||} and Nicola Della Ca,^{*,†}

[†]Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, 43124 Parma, Italy


[‡]Biopharmanet-tec, Parco delle Scienze, 27/A, 43124 Parma, Italy

[§]Dipartimento di Chimica e Tecnologie Chimiche, Università della Calabria, 87036 Arcavacata di Rende, Cosenza, Italy

^{||}Theoretical Chemistry Research Group, Institute of Organic Chemistry, Research Centre for Natural Sciences, Budapest, Hungary

Supporting Information

ABSTRACT: The first organo-catalyzed synthesis of imidazolidin-2-ones and imidazol-2-ones via intramolecular hydroamidation of propargylic ureas is reported. The phosphazene base BEMP turned out to be the most active organo-catalyst compared with guanidine and amidine bases. Excellent chemo- and regioselectivities to five-membered cyclic ureas have been achieved under ambient conditions, with a wide substrate scope and exceptionally short reaction times (down to 1 min). A base-mediated isomerization step to an allenamide intermediate is the most feasible reaction pathway to give imidazol-2-ones, as suggested by DFT studies.



INTRODUCTION

Imidazol-2-ones and their analogues are omnipresent structural motifs of bioactive pharmaceutical compounds and natural alkaloids (Figure 1).¹ Five-membered cyclic ureas are also flexible key intermediates in synthetic transformations² and useful chiral auxiliaries in enantioselective syntheses.³

The high value of these heterocycles for synthetic and pharmaceutical chemistry has driven continuous efforts in the development of sustainable and more efficient protocols. Traditional synthetic routes to imidazolidin-2-ones are mainly

based on the carbonylation of diamines,⁴ which can require toxic carbonylating agents, high-pressure facilities, and harsh reaction conditions. Metal-catalyzed diamination of olefins⁵ and aziridine ring expansion⁶ are elegant strategies; however, the widespread application suffers from their inherent sophistication. The intramolecular hydroamidation approach⁷ offers a powerful, atom- and step-economical alternative route to easily access richly decorated five-membered cyclic ureas.^{4a,8,9} In this context, propargylureas have been extensively investigated as readily available precursors for the synthesis of both imidazolin-2-ones and imidazolidin-2-ones. The control of chemo- (O vs N cyclization) and regio- (exo- vs endo-) selectivity in the cyclization step is generally addressed by means of transition metal catalysts.^{8a–f,8,10} As a relevant example, a Ag(I)-catalyzed one-pot protocol for the synthesis of 2-imidazolones through cycloisomerization of an *in situ* formed propargylic urea was disclosed by Van der Eycken in 2011.^{8d} More recently, Reddy and co-workers have reported the synthesis of indole-fused cyclic urea derivatives through a Ag-catalyzed sequence that involves an elegant double intramolecular hydroamidation process.^{8b} These interesting methods require however a high catalyst loading (up to 30 mol %) and harsh reaction conditions. More sustainable metal-free protocols to efficiently access imidazol-2-ones and imidazolidin-




Figure 1. Selected bioactive 2-imidazol(idin)one derivatives.

Received: January 8, 2019

Published: February 21, 2019

din-2-ones from propargylic ureas have been also developed by using a *stoichiometric* amount of bases or salts.⁹ For instance, Dethe and Lubell have recently proposed the use of NaOH^{9a} and NaH^{9b} for the synthesis of imidazole-2-thione and *N*-amino-imidazolin-2-ones, respectively, under mild conditions. Despite the usefulness of these methods, a base-catalyzed intramolecular hydroamidation approach to imidazol-2-one derivatives is still in high demand and, to date, totally unprecedented.


Herein, we disclose the first base-catalyzed intramolecular hydroamidation of propargylic ureas to highly substituted imidazolidin-2-ones and imidazol-2-ones. Notable features of our methodology include (i) excellent chemo- and regioselectivity to five-membered cyclic ureas, (ii) a wide substrate scope and high functional group tolerance, (iii) very mild reaction conditions, and (iv) remarkably short reaction times. Further, thanks to key mechanistic insights on the reaction pathway, we demonstrated the feasibility of a one-pot step-economical protocol starting from propargyl amines and isocyanates.

RESULTS AND DISCUSSION

Inspired by our recent studies on the base-catalyzed synthesis of imidazolidin-2-ones from propargylamines, CO₂, and primary amines,¹¹ we started to investigate the intramolecular hydroamidation reaction of propargylic ureas.¹² Guanidine base TBD, widely exploited in a plethora of catalytic transformations,¹³ including the above-mentioned synthesis of imidazolidin-2-ones,¹¹ was initially employed as a catalyst for the hydroamidation of propargylic urea **1a** (Table 1) using similar reaction conditions. We found that propargylic urea **1a** in the presence of 10% of TBD at 100 °C in anhydrous acetonitrile converted quantitatively to imidazolidinone **2a** (Table 1, entry 1). Excellent results were also achieved at lower temperatures (Table 1, entries 2 and 3), and therefore, subsequent experiments were tested at rt (22–23 °C). A series of similar organic bases were then evaluated (Table 1, entries 4–7). MTBD and BTMG were found to be less effective, leading to imidazolidinone **2a** in 82% and 67% yield, respectively (Table 1, entries 4 and 5). On the contrary, DBU and TMG turned out to be totally inactive in promoting the desired cyclization (Table 1, entries 6 and 7). Notably, the catalytic activity seemed to follow the strength of the bases. We then resorted to 2-*tert*-butylimino-2-diethylamino-1,3-dimethylperhydro-1,3,2-diazaphosphorine (BEMP), which is a stronger base that proved to be useful in other hydroamination reactions.¹⁴ Gratifyingly, the use of 10 mol % of BEMP afforded **2a** in quantitative yield (Table 1, entry 8). Furthermore, the reaction time decreased dramatically to 30 min. This significant improvement allowed us to decrease the amount of catalyst down to 1 mol %, while still maintaining high reaction performance (Table 1, entries 9 and 10). Other solvents were then tested (Table 1, entries 11–13), and we found that MeCN was crucial to trigger an efficient reaction. Notably, the presence of water in the mixture, detrimental for other protocols,^{8d,9b} did not affect the final outcome (Table 1, entry 14). Finally, no reaction took place in the control experiment in the absence of catalyst (Table 1, entry 15).


To illustrate the scope of this methodology, a series of propargyl ureas bearing a quaternary carbon α to the triple bond were then prepared. Under optimal conditions (Table 1, entry 9), propargylic ureas **1a–l** reacted smoothly to give the corresponding imidazolidin-2-ones **2a–l** in excellent yields

Table 1. Optimization Study^a




entry	base (mol %)	solvent	<i>T</i> (°C)	time (h)	yield (%) ^b 2a
1	TBD (10)	MeCN	100	24	99
2	TBD (10)	MeCN	50	24	99
3	TBD (10)	MeCN	rt	24	99
4	MTBD (10)	MeCN	rt	24	82
5	BTMG (10)	MeCN	rt	24	67
6	DBU (10)	MeCN	rt	24	–
7	TMG (10)	MeCN	rt	24	–
8	BEMP (10)	MeCN	rt	0.5	99
9	BEMP (5)	MeCN	rt	1	99
10	BEMP (1)	MeCN	rt	7	93
11	BEMP (5)	EtOAc	rt	24	–
12	BEMP (5)	THF	rt	24	–
13	BEMP (5)	MeOH	rt	24	–
14	BEMP (5)	MeCN ^c	rt	1	99
15	–	MeCN	rt	24	–

^aReaction conditions: **1a** (0.4 mmol), base (1–10 mol %), solvent (4 mL). ^bYields of **2a** were determined via ¹H NMR analysis using methylbenzoate as internal standard. ^c0.4 mmol (1 equiv) of H₂O was added. ^dp*K*_a is referred to its conjugate acid in MeCN.¹³ ^eNot determined.¹⁴



(Table 2). Reactions reached completion within 1 to 16 h at rt. Both electron-donating (Me) and electron-withdrawing (F, CO₂Me) groups on the aryl substituent were well tolerated in this simple and robust methodology (**2b–d**, 82–98%). The reaction rate is slower increasing the hindrance on the carbon α to the triple bond (**2e** and **2f**, 3 and 16 h). However, the presence of a substituent on the nitrogen β to the triple bond caused a lower yield of the corresponding cyclic urea, as shown in the case of **2g** (R³ = Bn, 52%). Propargylic ureas bearing an internal triple bond led to the corresponding imidazolidin-2-ones in high yield (**2h–l**, 83–97%). Aryl and alkyl groups on the triple bond were well tolerated. In all cases, the *Z* product was the preferred one,¹⁵ although the stereocontrol was not complete. Ureas bearing an alkyl substituent in R⁴, such as *n*-Bu, were unreactive under these optimized conditions. Interestingly, urea **1m** that bears an ester group in a suitable position (R⁴ = CH₂CO₂Et) led to hydantoin **2m'** (72%),^{3c} leaving the triple bond untouched.


We also tested the reactivity of a propargylic thiourea, which is reported to give imidazole-2-thiones under basic conditions.^{9a} On the contrary, thiazolidin-2-imine **2n'** was

Table 2. Scope of the BEMP-Catalyzed Synthesis of Imidazolidin-2-ones **2**^{a,b}

^aReaction conditions: **1** (0.4 mmol), BEMP (5 mol %), MeCN (4 mL), room temperature. ^bYields of **2**. ^cThe reaction was performed at 40 °C. ^dCompound **2n'** was obtained directly from propargylic amine and isothiocyanate without catalyst (see SI for details).

selectively obtained directly from propargylic amine and isothiocyanate precursors through intramolecular S-cyclization without a catalyst. The structure of **2n'** was undoubtedly confirmed by SC-XRD (see the Supporting Information (SI) for details).¹⁵

We then further explored the substrate scope of the transformation by employing a variety of propargylic ureas **3** bearing a tertiary carbon α to the triple bond (Table 3). In this case, selective formation of imidazol-2-ones **4** was observed, with a formal double bond shift from the exo- to the endocyclic position. To our delight, reaction times were impressively shortened. Upon reagent mixing, the reaction completes in about 1 min. The protocol was again characterized by a remarkable tolerance of valuable functional groups, including Cl (**4i**, 86%), Br (**4k**, 68%), F (**4f**, 93%), OMe (**4h**, 77%), or vinyl (**4j**,¹⁵ 75%) substituents. It is worth noting that this ample tolerance ensures vast handles for further functionalizations. Alkyl substituents on the triple bond (R¹) or on terminal nitrogen (R⁴) gave low yields, as shown for example for **4b** and


Table 3. Scope of the BEMP-Catalyzed Synthesis of Imidazol-2-ones **4**^{a,b}

^aReaction conditions: **3** (0.4 mmol), BEMP (5 mol %), MeCN (4 mL), room temperature, 1 min. ^bYields of **4**.

4l (18% and 33% yield, respectively). Alkyl or benzyl substituents on nitrogen β to the triple bond (R³) led to an excellent yield of product **4**, even for more sterically demanding groups, as in the case of **4d** (93% yield). This is complementary to the trend observed with products **2** (**2g**, Table 2). Electronic effects exerted by substituents in the *para* position on the aromatic ring (R₁) were also explored. Urea **3n** bearing a tolyl group on the triple bond (R¹ = 4-MeC₆H₄) led to the corresponding imidazolone **4n** in 81% yield, which is slightly less than those observed for **4a** (R¹ = C₆H₅). The best results were obtained with electron-withdrawing groups, such as Cl (**4o**, 98%) and F (**4p**, 97%). Finally, the unsubstituted propargylic urea **3q** (R¹, R², R³ = H) did not provide the corresponding imidazolone **4q**, being unreactive under these conditions.

To further demonstrate the applicability of this protocol, the one-pot synthesis of imidazol-2-one derivatives starting from propargylic amines and isocyanates was performed under standard conditions. Gratifyingly, compound **2a** was quantitatively obtained in 1 h from 2-methylbut-3-yn-2-amine and phenyl isocyanate (Scheme 1a). Without further optimization, imidazolone **4a** was synthesized directly from the propargyl-

Scheme 1. Representative Examples of the One-Pot Synthesis of Imidazolidin-2-one **2a** and Imidazol-2-one **4a** from Propargylic Amines and Isocyanates



amine **3a** and phenyl isocyanate in 62% yield, using 10 mol % of BEMP (Scheme 1b). Noteworthy, this intermolecular reaction was still complete within 1 min.

Intrigued by the complete chemoselectivity and site selectivity features as well as by the unexpectedly fast formation of imidazol-2-ones **4** under very mild conditions, we carried out computational studies to gain insights into the reaction mechanism. Investigation began by employing the Gaussian09 package¹⁶ using the range separated, hybrid ω b97xd functional.¹⁷ The possible reaction routes have been studied in terms of solvent-corrected Gibbs free energy values (see SI for details). Figure 2 shows the most feasible




Figure 2. Gibbs free energy profile of the formation of imidazolidin-2-one **2a** (N-5-exo-dig cyclization pathway). Color code used for the effect of bases: (blue) BEMP as base; (green, from top to bottom) TMG, DBU, TBD, MTBD, BTMG as base.²¹

mechanism to generate imidazolidin-2-one **2a** from propargylic urea **1a**. The reaction starts with the abstraction of the most acidic urea proton by the base, which is a slightly endergonic process. We obtained good correlation between the pK_a of the bases and the endergonicity of the deprotonation step.¹⁸ The levels obtained with the strongest base (BEMP) are shown in blue. The deprotonation yields **1a-D-BEMPH+** (ΔG +5.5 kcal/mol). We observed that, upon this proton transfer, the conjugated acid/base pair dissociates as higher ΔG values were obtained modeling a tight ion pair. We explained this by the entropy penalty of the association of the two ions,¹⁹ and also by the enhanced solvation of the two independent ions which together boost therefore dissociation in the polar MeCN solvent. The deprotonated urea can then react with the triple bond in four different ways depending on the cyclization fashion. N- or O-carbon bond formation occurs via either 5-exo- or 6-endo-dig cyclization modes. The formation of the

anionic form of product **2a** (**2a-D-N5**) is the most favorable pathway both kinetically and thermodynamically (not shown here; see SI, Figure S1). Eventually, the cyclization is followed by the strongly exergonic protonation yielding the product **2a** (ΔG -36.7 kcal/mol). The rate-determining step is the cyclization, which requires a moderate 20.8 kcal/mol activation free energy (from **1a** to **TS-N5**) in the presence of BEMP. This is fully compatible with the observed reaction rate.²⁰ The calculated trend among different bases evenly correlates with the experimental results listed in Table 1. Indeed, stronger bases proved to be better catalysts, as they can more easily deprotonate the substrate (Figure 2).

Second, formation of imidazol-2-one **4a** from **3a** was investigated. The initial base-catalyzed isomerization of the triple bond to the corresponding allenamide was the most favored pathway to imidazol-2-ones **4a** (Figure 3, blue




Figure 3. Gibbs free energy profile of the formation of imidazol-2-one **4a**, employing BEMP as catalyst. Blue profile: allenamide route. Green profile: mechanism analogue to the one presented in Figure 2.

pathway). The proton of **3a** highlighted in red became the most acidic one. This ensures that the initial allenamide formation is preferred to urea deprotonation (Figure 3, green pathway). Hence, the resting state under the reaction conditions is allenamide **I₁**. Isomerization of the propargylic arm to the corresponding allenamide is highly plausible under strongly basic conditions.²² Then, the N-H deprotonation can occur and leads to the formation of the imidazol-2-one ring (**4a-D-1**) through a low barrier transition state. The final protonation yields the neutral product in a highly exergonic step. The calculations confirmed that the central carbon of the allene moiety is the most electron-deficient,²³ which explains the preference for the five-membered ring formation. The barrier for the cyclization step is only 12.5 kcal/mol (from **I₁** to **TS₃₋₄**). This suggests a very fast reaction, in perfect agreement with the experimental observations.²⁴

CONCLUSION

In summary, we have developed the first organo-catalyzed method to access imidazolidin-2-ones and imidazol-2-ones from propargylureas under ambient conditions. The protocol is simple, tolerates the presence of water, and provides five-membered cyclic ureas with excellent space-time yields. DFT calculations provided support for the nonassisted cyclization of deprotonated urea in the imidazolidin-2-one formation and revealed the involvement of an allene intermediate in the imidazol-2-one pathway. The one-pot protocol starting from propargylic amines and isocyanates was also demonstrated. We

anticipate that the unique features of this method will ensure wide interest and vast application within the chemistry community at large.

EXPERIMENTAL SECTION

General Methods. All chemicals were purchased from commercial sources and used as received, unless otherwise noted. Solvents were dried and stored over molecular sieves previously activated in an oven (450 °C overnight). Organocatalyzed reactions were carried out under nitrogen using standard Schlenk techniques. Reactions were analyzed by thin layer chromatography (TLC) on silica gel 60 F254. GC analyses were performed with an Agilent Technologies 7820A equipped with an FID detector and a 30 m capillary column. GC-MS analyses (*m/z*, relative intensity%) were performed with an Agilent Technologies 6890N gas chromatograph coupled to a 5973N mass selective detector (Agilent Technologies) working at 70 eV ionizing voltage. Column chromatography was performed on silica gel 60 (70–230 mesh). ¹H, ¹³C, and ¹⁹F NMR spectra were recorded at 300 K on a Bruker Avance 400 or 300 MHz using the solvent as the internal standard (7.26 ppm for ¹H NMR and 77.00 ppm for ¹³C NMR for CDCl₃). The terms m, s, d, t, q, and quint represent multiplet, singlet, doublet, triplet, quadruplet, and quintuplet, respectively, and the term br means a broad signal. Exact masses were recorded on an LTQ ORBITRAP XL Thermo Mass Spectrometer (ESI source). Melting points were measured with an electrothermal apparatus and are uncorrected.

Experimental Procedures. Synthesis of Propargylic Ureas 1a–f, 1m, 3q.²⁵ A dry round-bottom two-necked flask, containing a magnetic stir bar, was charged with the selected isocyanate (2.5 mmol), the desired propargylic amine (2.5 mmol), and dry THF (25 mL). The resulting mixture was stirred at room temperature overnight. The solvent was removed under reduced pressure. Yields were quantitative, and propargylic ureas 1a–f, 1m, and 3q were employed without further purification.

Synthesis of Propargylic Ureas 1i–l through Sonogashira Coupling.²⁶ A Schlenk-type flask equipped with a magnetic stir bar was charged with Pd(PPh₃)₂Cl₂ (0.02 mmol, 2 mol %, 14 mg), CuI (0.07 mmol, 7 mol %, 13 mg), and Et₃N (5 mL) under an inert atmosphere (N₂). The aryl iodide (1 mmol, 1 equiv) and the propargylic urea (1.2 equiv) were dissolved in dry CH₂Cl₂ (7 mL) and then added. The reaction mixture was stirred at room temperature overnight. The crude mixture was filtered through a fritted funnel, the solid residue was washed with CH₂Cl₂, and the combined organic solutions were concentrated under reduced pressure. Purification via flash column chromatography yielded the desired propargyl urea.

Synthesis of Propargylic Urea 1g.²⁷ A solution of 2-methylbut-3-yn-2-amine (5 mmol, 519 μL) and benzaldehyde (5 mmol, 507 μL) in MeOH (10 mL) was stirred at room temperature overnight. Sodium borohydride (10 mmol, 378 mg) was then added to the reaction mixture at 0 °C for 1 h under stirring. Then the reaction crude was diluted with water (25 mL) and extracted with CH₂Cl₂ (3 × 40 mL). The organic layers were combined, dried over MgSO₄, filtered, and concentrated under reduced pressure. The crude reaction mixture was purified by silica gel column chromatography (Eluent: hexane/ethyl acetate 7:3) to afford *N*-benzyl-2-methylbut-3-yn-2-amine in 55% yield (476 mg).

A dry round-bottom two-necked flask, containing a magnetic stir bar, was charged with phenyl isocyanate (2.5 mmol, 297 mg), *N*-benzyl-2-methylbut-3-yn-2-amine (2.5 mmol, 432 mg), and dry THF (25 mL).²⁵ The resulting mixture was stirred at room temperature for 1 h. The solvent was removed under reduced pressure. The yield is quantitative, and propargylic urea 1g was employed without further purification.

Synthesis of *N*-Benzyl-2-methyldodec-3-yn-2-amine.²⁸ A test tube equipped with a magnetic stirrer was charged with CuI (0.6 mmol, 30% mol, 114 mg). The test tube was sealed and flushed with N₂ and then was charged with dec-1-yne (2 mmol, 361 μL), acetone (2 mmol, 147 μL), and benzylamine (2 mmol, 219 μL). The test tube was then placed in an oil bath at 75 °C, and it was allowed to stir

overnight. The crude was purified by flash column chromatography using hexane/ethyl acetate (9:1) as eluent to give the desired amine (206 mg, 31% yield) as a transparent oil.

Synthesis of α -Monosubstituted Propargylic Amines.²⁸ In a typical experiment, CuI (0.6 mmol, 30% mol, 114 mg) was charged in a test tube equipped with a magnetic stirrer. The test tube was sealed and flushed with N₂ and then was charged with the alkyne (2 mmol), the aldehyde (2 mmol), and the amine (2 mmol). The test tube was then placed in an oil bath at 75 °C, and it was allowed to stir overnight. The crude reaction mixture was purified by silica gel column chromatography with a mixture of hexane/ethyl acetate (from 95:5 to 80:20) to provide the desired secondary propargylic amine.

Synthesis of Propargylic Ureas 1h and 3a–p.²⁵ A dry round-bottom two-necked flask, containing a magnetic stir bar, was charged with the selected isocyanate (1 mmol), the desired propargylic amine (1 mmol), and dry THF (10 mL). The resulting mixture was stirred at room temperature for 1 h. The solvent was removed under reduced pressure. Yields were quantitative for propargylic ureas 3a–k, 3n–p, which were employed without further purification. Silica gel column chromatography (Eluent: hexane/ethyl acetate) was required to isolate propargylic ureas 3l and 3m with 45% and 62% yield, respectively.

General Procedure for the BEMP-Catalyzed Synthesis of Imidazolidin-2-ones 2 (Table 2). A test tube, equipped with a magnetic stir bar, was charged with propargylic urea 1 (0.4 mmol) and CH₃CN (4 mL). BEMP (5 mol %, 6 μL) was added. The reaction mixture was stirred at room temperature and monitored by TLC. After completion, the solvent was removed under reduced pressure. The crude was purified by silica gel column chromatography with the mixture hexane/ethyl acetate.

General Procedure for the BEMP-Catalyzed Synthesis of Imidazol-2-ones 4 (Table 3). A test tube, equipped with a magnetic stir bar, was charged with propargylic urea 3 (0.4 mmol) and CH₃CN (4 mL). BEMP (5 mol %, 6 μL) was added. The reaction mixture was stirred at room temperature for 1 min (TLC confirmed the completion of the reaction). The solvent was removed under reduced pressure. The crude was purified by silica gel column chromatography with the mixture hexane/ethyl acetate.

One-Pot BEMP-Catalyzed Synthesis of 2a from Propargylic Amine and Isocyanate (Scheme 1a). A test tube, equipped with a magnetic stir bar, was charged with 2-methylbut-3-yn-2-amine (0.4 mmol, 33 mg), phenyl isocyanate (0.4 mmol, 48 mg), and CH₃CN (4 mL). BEMP (5 mol %, 6 μL) was added. The reaction mixture was stirred at room temperature and monitored by TLC. After completion (1 h), the solvent was removed under reduced pressure. The crude was purified by silica gel column chromatography (Eluent: hexane/ethyl acetate 1:1) to afford 2a in quantitative yield (81 mg).

One-Pot BEMP-Catalyzed Synthesis of 4a from Propargylic Amine and Isocyanate (Scheme 1b). A test tube, equipped with a magnetic stir bar, was charged with *N*-benzyl-1,3-diphenylprop-2-yn-1-amine (0.4 mmol, 119 mg), phenyl isocyanate (0.4 mmol, 48 mg), and CH₃CN (4 mL). BEMP (5 mol %, 6 μL) was added. The reaction mixture was stirred at room temperature for 1 min. Solvent was removed under reduced pressure. The crude was purified by silica gel column chromatography (Eluent: hexane/ethyl acetate 6:4) to afford 4a in 51% yield (85 mg). With 10% of BEMP, 4a was isolated in 62% yield (103 mg).

Synthesis of 2n'.²⁵ A dry two-necked flask containing a magnetic stir bar was charged with 1-fluoro-4-isothiocyanatobenzene (1 mmol, 122 μL), 2-methylbut-3-yn-2-amine (1 mmol, 105 μL), and dry THF (10 mL). The resulting mixture was stirred at room temperature and monitored by TLC. After 3 h, the solvent was removed under reduced pressure. The crude did not require purification, and product 2n' was recovered in 98% yield (231 mg) as a yellow solid.

***N*-Benzyl-2-methyldodec-3-yn-2-amine.** *N*-Benzyl-2-methyldodec-3-yn-2-amine was synthesized from 2 mmol of starting materials, according to the general procedure.²⁸ The crude was purified by flash column chromatography using hexane/ethyl acetate (9:1) as eluent to give the desired amine (206 mg, 31% yield) as a transparent oil. ¹H NMR (400 MHz, CDCl₃) δ 7.40–7.35 (m, 2H), 7.34–7.30 (m, 2H),

7.25–7.22 (m, 1H), 3.88 (s, 2H), 2.23 (t, $J = 7.0$ Hz, 2H), 1.59–1.49 (m, 2H), 1.47–1.42 (m, 2H), 1.40 (s, 6H), 1.34–1.27 (m, 9H), 0.90 (t, $J = 6.8$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 141.2, 128.6, 128.5, 126.9, 85.3, 82.4, 50.3, 49.2, 32.0, 30.1, 29.4, 29.2 (2C), 29.0, 22.8, 18.8, 14.2. HRMS (ESI) calcd for $\text{C}_{20}\text{H}_{32}\text{N}$ ($\text{M} + \text{H}$) $^+$ m/z 286.2535, found m/z 286.2533.

***N*-Benzyl-2-methylbut-3-yn-2-amine.** *N*-Benzyl-2-methylbut-3-yn-2-amine was synthesized according to the general procedure.²⁷ The crude was purified by flash column chromatography using hexane/ethyl acetate (7:3) as eluent to give the desired amine (476 mg, 55% yield) as a white solid; mp (hexane) 44.7–45.3 °C. ^1H NMR (300 MHz, CDCl_3) δ 7.43–7.33 (m, 4H), 7.31–7.26 (m, 1H), 3.91 (s, 2H), 2.39 (s, 1H), 1.46 (two overlapping signals: brs and s, 7H). Spectroscopic data were consistent with literature values.²⁹

***N*-Benzyl-1,3-diphenylprop-2-yn-1-amine.** *N*-Benzyl-1,3-diphenylprop-2-yn-1-amine was synthesized according to the general procedure.²⁸ The crude was purified by flash column chromatography using hexane/ethyl acetate (8:2) as eluent to give the desired amine (349 mg, 59% yield) as a viscous colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 7.69 (d, $J = 7.4$ Hz, 2H), 7.59–7.55 (m, 2H), 7.50–7.41 (m, 5H), 7.40–7.36 (m, 5H), 7.35–7.31 (m, 1H), 4.88 (s, 1H), 4.12–4.00 (m, 2H), 2.01 (bs, 1H). Spectroscopic data were consistent with literature values.³⁰

***N*-Benzyl-1-phenylundec-2-yn-1-amine.** *N*-Benzyl-1-phenylundec-2-yn-1-amine was synthesized according to the general procedure.²⁸ The crude was purified by flash column chromatography using hexane/ethyl acetate (9:1) as eluent to give the desired amine (342 mg, 53% yield) as a yellowish oil. ^1H NMR (400 MHz, CDCl_3) δ 7.63 (d, $J = 7.4$ Hz, 2H), 7.48–7.41 (m, 4H), 7.40–7.37 (m, 2H), 7.36–7.29 (m, 2H), 4.65 (s, 1H), 4.04–3.94 (m, 2H), 2.37 (further split t, $J = 7.0$ Hz, 2H), 1.79 (bs, 1H), 1.70–1.60 (m, 2H), 1.57–1.48 (m, 2H), 1.44–1.34 (m, 8H), 0.98 (t, $J = 6.9$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 141.1, 140.1, 128.5, 128.4, 128.2, 127.7, 127.5, 127.0, 86.1, 79.9, 53.3, 51.1, 31.9, 29.3, 29.2, 29.0, 28.9, 22.8, 18.9, 14.2. HRMS (ESI) calcd for $\text{C}_{24}\text{H}_{32}\text{N}$ ($\text{M} + \text{H}$) $^+$ m/z 334.2534, found m/z 334.2530.

***N*-(1,3-Diphenylprop-2-yn-1-yl)butan-1-amine.** *N*-Benzyl-1,3-diphenylprop-2-yn-1-amine was synthesized according to the general procedure.²⁸ The crude was purified by flash column chromatography using hexane/ethyl acetate (8:2) as eluent to give the desired amine (315 mg, 60% yield) as a viscous yellow oil. ^1H NMR (300 MHz, CDCl_3) δ 7.68 (d, $J = 7.2$ Hz, 2H), 7.62–7.50 (m, 2H), 7.49–7.40 (m, 2H), 7.39–7.32 (m, 4H), 4.88 (s, 1H), 2.98–2.88 (m, 1H), 2.86–2.70 (m, 1H), 1.64–1.38 (m, 4H), 1.00 (t, $J = 7.3$ Hz, 3H). Spectroscopic data were consistent with literature values.³¹

1,3-Diphenyl-*N*-(1-phenylethyl)prop-2-yn-1-amine. 1,3-Diphenyl-*N*-(1-phenylethyl)prop-2-yn-1-amine was synthesized according to the general procedure.²⁸ The crude was purified by flash column chromatography using hexane/ethyl acetate (9:1) as eluent to give the desired amine (257 mg, 42% yield) together with the corresponding imine intermediate.³² ^1H NMR (400 MHz, CDCl_3) δ 7.62–7.31 (m, 30H), 4.71 (s, 1H), 4.50 (s, 1H), 4.40 (q, $J = 6.6$ Hz, 1H), 3.96 (q, $J = 6.6$ Hz, 1H), 1.76 (brs, 2H), 1.45 (d, $J = 6.6$ Hz, 3H), 1.42 (d, $J = 6.6$ Hz, 3H). Spectroscopic data were consistent with literature values.³²

***N*-(4-Methylbenzyl)-1,3-diphenylprop-2-yn-1-amine.** *N*-(4-Methylbenzyl)-1,3-diphenylprop-2-yn-1-amine was synthesized according to the general procedure.²⁸ The crude was purified by flash column chromatography using hexane/ethyl acetate (9:1) as eluent to give the desired amine (433 mg, 70% yield) as a viscous yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.78 (d, $J = 7.2$ Hz, 2H), 7.69–7.66 (m, 2H), 7.53 (t, $J = 7.4$ Hz, 2H), 7.49–7.44 (m, 6H), 7.30 (d, $J = 7.8$ Hz, 2H), 4.96 (s, 1H), 4.12 (s, 2H), 2.49 (s, 3H), 1.98 (bs, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 140.4, 136.8, 136.6, 131.8, 129.1, 128.5, 128.4, 128.3, 128.2, 127.8, 127.7, 123.2, 89.4, 85.7, 53.6, 50.9, 21.2. HRMS (ESI) calcd for $\text{C}_{23}\text{H}_{22}\text{N}$ ($\text{M} + \text{H}$) $^+$ m/z 312.1752, found m/z 312.1754.

***N*-(4-Fluorobenzyl)-1,3-diphenylprop-2-yn-1-amine.** *N*-(4-Fluorobenzyl)-1,3-diphenylprop-2-yn-1-amine was synthesized according to the general procedure.²⁸ The crude was purified by flash column chromatography using hexane/ethyl acetate (9:1) as eluent to give the

desired amine (490 mg, 78% yield) as a viscous yellowish oil. ^1H NMR (400 MHz, CDCl_3) δ 7.73–7.68 (m, 2H), 7.62–7.57 (m, 2H), 7.49–7.42 (m, 4H), 7.42–7.36 (m, 4H), 7.13–7.07 (m, 2H), 4.87 (s, 1H), 4.04 (s, 2H), 1.89 (bs, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 162.1 (d, $J_{\text{C,F}} = 244.8$ Hz), 135.6 (d, $J_{\text{C,F}} = 3.1$ Hz), 140.3, 131.8, 130.0 (d, $J_{\text{C,F}} = 7.9$ Hz), 128.6, 128.4, 128.3, 127.9, 127.7, 123.1, 115.2 (d, $J_{\text{C,F}} = 21.2$ Hz), 89.2, 85.9, 53.6, 50.4. $^{19}\text{F}\{^1\text{H}\}$ NMR (376 MHz, CDCl_3) δ –115.56. HRMS (ESI) calcd for $\text{C}_{22}\text{H}_{18}\text{FN}$ ($\text{M} + \text{H}$) $^+$ m/z 316.1501, found m/z 316.1498.

***N*-Benzyl-3-phenyl-1-(*p*-tolyl)prop-2-yn-1-amine.** *N*-Benzyl-3-phenyl-1-(*p*-tolyl)prop-2-yn-1-amine was synthesized according to the general procedure.²⁸ The crude was purified by flash column chromatography using hexane/ethyl acetate (9:1) as eluent to give the desired amine (533 mg, 86% yield) as a viscous colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 7.69–7.65 (m, 2H), 7.61–7.56 (m, 4H), 7.53–7.40 (m, 7H), 7.27 (d, $J = 7.8$ Hz, 1H), 4.94 (s, 1H), 4.21–4.12 (m, 2H), 2.53 (s, 3H), 2.11 (bs, 1H). Spectroscopic data were consistent with literature values.³³

***N*-Benzyl-1-(4-methoxyphenyl)-3-phenylprop-2-yn-1-amine.** *N*-Benzyl-1-(4-methoxyphenyl)-3-phenylprop-2-yn-1-amine was synthesized according to the general procedure.²⁸ The crude was purified by flash column chromatography using hexane/ethyl acetate (8:2) as eluent to give the desired amine (376 mg, 58% yield) as a yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.68–7.59 (m, 4H), 7.54–7.49 (m, 2H), 7.46–7.39 (m, 5H), 7.38–7.33 (m, 1H), 7.04–6.98 (m, 2H), 4.88 (s, 1H), 4.12–4.03 (m, 2H), 3.88 (s, 3H), 1.94 (bs, 1H). Spectroscopic data were consistent with literature values.³⁰

***N*-Benzyl-1-(3-chlorophenyl)-3-phenylprop-2-yn-1-amine.** *N*-Benzyl-1-(3-chlorophenyl)-3-phenylprop-2-yn-1-amine was synthesized according to the general procedure.²⁸ The crude was purified by flash column chromatography using hexane/ethyl acetate (9:1) as eluent to give the desired amine (342 mg, 52% yield) as dark yellow oil. ^1H NMR (300 MHz, CDCl_3) δ 7.75–7.72 (m, 1H), 7.63–7.58 (m, 3H), 7.53–7.48 (m, 2H), 7.47–7.40 (m, 5H), 7.39–7.34 (m, 3H), 4.87 (s, 1H), 4.07 (s, 2H), 2.03 (bs, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 142.4, 139.6, 134.4, 131.8, 129.8, 128.6, 128.5, 128.4 (2C), 128.0, 127.9, 127.2, 125.9, 122.9, 88.5, 86.3, 53.2, 51.1. HRMS (ESI) calcd for $\text{C}_{22}\text{H}_{18}\text{ClN}$ ($\text{M} + \text{H}$) $^+$ m/z 332.1206, found m/z 332.1203.

***N*-Benzyl-3-phenyl-1-(3-vinylphenyl)prop-2-yn-1-amine.** *N*-Benzyl-3-phenyl-1-(3-vinylphenyl)prop-2-yn-1-amine was synthesized according to the general procedure.²⁸ The crude was purified by flash column chromatography using hexane/ethyl acetate (9:1) as eluent to give the desired amine (504 mg, 78% yield) as a yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.83 (s, 1H), 7.71–7.63 (m, 3H), 7.57 (d, $J = 7.1$ Hz, 2H), 7.53–7.39 (m, 8H), 6.90 (dd, $J = 17.6$, 10.9 Hz, 1H), 5.94 (d, $J = 17.6$, 1H), 5.42 (d, $J = 10.9$ Hz, 1H), 4.97 (s, 1H), 4.19–4.11 (m, 2H), 2.11 (bs, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 140.6, 139.8, 137.8, 136.8, 131.8, 128.7, 128.4 (2C), 128.3, 128.2, 127.2, 127.1, 125.7, 125.6, 123.1, 114.1, 89.2, 85.8, 53.6, 51.1. HRMS (ESI) calcd for $\text{C}_{24}\text{H}_{22}\text{N}$ ($\text{M} + \text{H}$) $^+$ m/z 324.1752, found m/z 324.1755.

***N*-Benzyl-1-(2-bromophenyl)-3-phenylprop-2-yn-1-amine.** *N*-Benzyl-1-(2-bromophenyl)-3-phenylprop-2-yn-1-amine was synthesized according to the general procedure.²⁸ The crude was purified by flash column chromatography using hexane/ethyl acetate (9:1) as eluent to give the desired amine (558 mg, 74% yield) as a viscous pale orange oil. ^1H NMR (400 MHz, CDCl_3) δ 7.92 (dd, $J = 7.7$, 1.7 Hz, 1H), 7.64 (dd, $J = 8.0$, 1.2 Hz, 1H), 7.61–7.56 (m, 2H), 7.50 (d, $J = 6.9$ Hz, 2H), 7.42–7.37 (m, 6H), 7.36–7.31 (m, 1H), 7.24–7.19 (m, 1H), 5.28 (s, 1H), 4.12–4.02 (m, 2H), 2.03 (bs, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 139.5, 139.4, 133.2, 131.8, 129.6, 129.4, 128.7, 128.4, 128.3 (2C), 127.8, 127.2, 123.8, 123.0, 88.4, 85.8, 53.7, 51.7. HRMS (ESI) calcd for $\text{C}_{22}\text{H}_{19}\text{BrN}$ ($\text{M} + \text{H}$) $^+$ m/z 376.0700, found m/z 376.0703.

***N*-Benzyl-1-phenyl-3-(*p*-tolyl)prop-2-yn-1-amine.** *N*-Benzyl-1-phenyl-3-(*p*-tolyl)prop-2-yn-1-amine was synthesized according to the general procedure.²⁸ The crude was purified by flash column chromatography using hexane/ethyl acetate (9:1) as eluent to give the desired amine (280 mg, 45% yield) as a viscous yellow oil. ^1H NMR

(400 MHz, CDCl₃) δ 7.66 (d, J = 7.3 Hz, 2H), 7.48–7.41 (m, 5H), 7.40–7.35 (m, 3H), 7.35–7.26 (m, 2H), 7.17 (d, J = 7.9 Hz, 2H), 4.84 (s, 1H), 4.08–3.98 (m, 2H), 2.40 (s, 3H), 1.91 (bs, 1H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 140.5, 139.9, 138.4, 131.8, 129.2, 128.61 (2C), 128.56, 127.9, 127.8, 127.2, 120.2, 88.5, 86.0, 53.8, 51.2, 21.6. HRMS (ESI) calcd for C₂₃H₂₂N (M + H)⁺ m/z 312.1752, found m/z 312.1751.

N-Benzyl-3-(4-chlorophenyl)-1-phenylprop-2-yn-1-amine. N-Benzyl-3-(4-chlorophenyl)-1-phenylprop-2-yn-1-amine was synthesized according to the general procedure.²⁸ The crude was purified by flash column chromatography using hexane/ethyl acetate (8:2) as eluent to give the desired amine (358 mg, 54% yield) as a viscous dark yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.64 (d, J = 7.3 Hz, 2H), 7.47–7.38 (m, 7H), 7.38–7.27 (m, 5H), 4.84 (s, 1H), 4.09–3.94 (m, 2H), 2.01 (bs, 1H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 140.2, 139.8, 134.3, 133.1, 128.8, 128.7, 128.6, 128.5, 128.0, 127.7, 127.2, 121.6, 90.5, 84.7, 53.8, 51.3. HRMS (ESI) calcd for C₂₂H₁₉ClN (M + H)⁺ m/z 332.1206, found m/z 332.1207.

N-Benzyl-3-(4-fluorophenyl)-1-phenylprop-2-yn-1-amine. N-Benzyl-3-(4-fluorophenyl)-1-phenylprop-2-yn-1-amine was synthesized according to the general procedure.²⁸ The crude was purified by flash column chromatography using hexane/ethyl acetate (8:2) as eluent to give the desired amine (265 mg, 42% yield) as a viscous yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.69–7.62 (m, 2H), 7.54–7.48 (m, 2H), 7.48–7.34 (m, 7H), 7.33–7.28 (m, 1H), 7.10–7.01 (m, 2H), 4.84 (s, 1H), 4.11–3.96 (m, 2H), 1.89 (s, 1H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 162.51 (d, $J_{C,F}$ = 249.2 Hz), 140.35, 139.84, 133.67 (d, $J_{C,F}$ = 8.3 Hz), 128.64, 128.55, 128.51, 127.93, 127.73, 127.23, 119.27 (d, $J_{C,F}$ = 3.5 Hz), 115.62 (d, $J_{C,F}$ = 22.0 Hz), 89.05, 84.72, 53.73, 51.26. ¹⁹F{¹H} NMR (376 MHz, CDCl₃) δ –111.03. HRMS (ESI) calcd for C₂₂H₁₉FN (M + H)⁺ m/z 316.1501, found m/z 332.1498.

1-(2-Methylbut-3-yn-2-yl)-3-phenylurea (1a). Compound 1a was synthesized according to the general procedure.²⁵ The crude was dried under vacuum and used without purification. Compound 1a was obtained as a white solid; mp (hexane) 116.3–117.6 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.28 (bs, 1H), 7.36 (d further split, 2H), 7.26–7.17 (m, 2H), 6.95–6.83 (m, 1H), 6.38 (bs, 1H), 3.10 (s, 1H), 1.54 (s, 6H). ¹³C{¹H} NMR (101 MHz, DMSO-*d*₆) δ 153.8, 140.2, 128.6, 121.1, 117.5, 88.5, 70.7, 46.0, 29.3. HRMS (ESI) calcd for C₁₂H₁₄N₂NaO (M + Na)⁺ m/z 225.1004, found m/z 225.1008.

1-(2-Methylbut-3-yn-2-yl)-3-(*p*-tolyl)urea (1b). Compound 1b was synthesized according to the general procedure.²⁵ The crude was dried under vacuum and used without purification. Compound 1b was obtained as a white solid; mp (hexane) 144.4–146.1 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.19 (bs, 1H), 7.25 (d, J = 8.4 Hz, 2H), 7.03 (d, J = 8.3 Hz, 2H), 6.34 (bs, 1H), 3.11 (s, 1H), 2.22 (s, 3H), 1.54 (s, 6H). ¹³C{¹H} NMR (101 MHz, DMSO-*d*₆) δ 153.9, 137.7, 129.8, 129.0, 117.6, 88.7, 70.7, 46.0, 29.4, 20.3. HRMS (ESI) calcd for C₁₃H₁₆N₂NaO (M + Na)⁺ m/z 239.1160, found m/z 239.1158.

1-(4-Fluorophenyl)-3-(2-methylbut-3-yn-2-yl)urea (1c). Compound 1c was synthesized according to the general procedure.²⁵ The crude was dried under vacuum and used without purification. Compound 1c was obtained as a light purple solid; mp (hexane) 174.1–174.8 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.33 (bs, 1H), 7.41–7.30 (m, 2H), 7.09–7.01 (m, 2H), 6.38 (bs, 1H), 3.11 (s, 1H), 1.53 (s, 6H). ¹³C{¹H} NMR (101 MHz, DMSO-*d*₆) δ 156.9 (d, $J_{C,F}$ = 237.2 Hz), 153.9, 136.6 (d, $J_{C,F}$ = 2.3 Hz), 119.1 (d, $J_{C,F}$ = 7.5 Hz), 115.1 (d, $J_{C,F}$ = 22.0 Hz), 88.6, 70.8, 46.0, 29.4. ¹⁹F{¹H} NMR (376 MHz, DMSO-*d*₆) δ –122.40. HRMS (ESI) calcd for C₁₂H₁₃FN₂NaO (M + Na)⁺ m/z 243.0910, found m/z 243.0912.

Methyl 4-(3-(2-Methylbut-3-yn-2-yl)ureido)benzoate (1d). Compound 1d was synthesized according to the general procedure.²⁵ The crude was dried under vacuum and used without purification. Compound 1d was obtained as a white solid; mp (hexane) 189.6–190.9 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.73 (bs, 1H), 7.86–7.81 (m, 2H), 7.52–7.48 (m, 2H), 6.58 (bs, 1H), 3.79 (s, 3H), 3.10 (s, 1H), 1.55 (s, 6H). ¹³C{¹H} NMR (101 MHz, DMSO-*d*₆) δ 166.0, 153.4, 144.9, 130.4, 121.9, 116.7, 88.3, 70.8, 51.6, 46.2, 29.2. HRMS

(ESI) calcd for C₁₄H₁₆N₂NaO₃ (M + Na)⁺ m/z 283.1059, found m/z 283.1057.

1-(3-Ethylpent-1-yn-3-yl)-3-phenylurea (1e). Compound 1e was synthesized according to the general procedure.²⁵ The crude was dried under vacuum and used without purification. Compound 1e was obtained as a white solid; mp (hexane) 122.3–123.1 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.98 (bs, 1H), 7.35 (d, J = 7.6 Hz, 2H), 7.21 (t, J = 7.9 Hz, 2H), 6.97 (t, J = 7.4 Hz, 1H), 5.85 (bs, 1H), 2.32 (s, 1H), 2.01–1.78 (m, 2H), 1.76–1.53 (m, 2H), 0.99 (t, J = 7.4 Hz, 6H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 155.5, 139.2, 128.9, 122.8, 119.8, 85.8, 71.8, 55.6, 31.4, 8.5. HRMS (ESI) calcd for C₁₄H₁₈N₂NaO (M + Na)⁺ m/z 253.1317, found m/z 253.1320.

1-(1-Ethynylcyclohexyl)-3-phenylurea (1f). Compound 1f was synthesized according to the general procedure.²⁵ The crude was dried under vacuum and used without purification. Compound 1f was obtained as a white solid; mp (hexane) 157.2–157.8 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.32 (bs, 1H), 7.36 (d, J = 7.6 Hz, 2H), 7.22 (t, J = 7.9 Hz, 2H), 6.89 (t, J = 7.3 Hz, 1H), 6.29 (bs, 1H), 3.15 (s, 1H), 2.08–1.92 (m, 2H), 1.81–1.69 (m, 2H), 1.62–1.43 (m, 5H), 1.34–1.22 (m, 1H). ¹³C{¹H} NMR (101 MHz, DMSO-*d*₆) δ 154.2, 140.8, 129.1, 121.5, 117.9, 87.6, 73.3, 50.6, 37.3, 25.3, 22.4. HRMS (ESI) calcd for C₁₅H₁₈N₂NaO (M + Na)⁺ m/z 265.1317, found m/z 265.1319.

1-Benzyl-1-(2-methylbut-3-yn-2-yl)-3-phenylurea (1g). Compound 1g was synthesized according to the general procedure.²⁷ Compound 1g was obtained as colorless oil; ¹H NMR (300 MHz, CDCl₃) δ 7.47–7.41 (m, 4H), 7.37–7.31 (m, 2H), 7.29–7.23 (m, 4H), 6.95 (bs, 1H), 4.85 (s, 2H), 2.56 (s, 1H), 1.88 (s, 6H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 156.2, 139.3, 139.2, 129.2, 128.9, 127.6, 126.5, 123.1, 119.8, 88.1, 72.8, 54.8, 50.1, 29.2. HRMS (ESI) calcd for C₁₉H₂₀N₂NaO (M + Na)⁺ m/z 315.1473, found m/z 315.1476.

1-Benzyl-1-(2-methyldec-3-yn-2-yl)-3-phenylurea (1h). Compound 1h was synthesized according to the general procedure.²⁶ The crude was purified by silica gel column chromatography to obtain 1h with a 78% yield (352 mg) as a yellowish oil. ¹H NMR (400 MHz, CDCl₃) δ 7.51 (bs, 1H), 7.44–7.34 (m, 4H), 7.33–7.24 (m, 5H), 7.05–6.98 (m, 1H), 4.87 (s, 2H), 2.21 (t, J = 7.0 Hz, 2H), 1.80 (s, 6H), 1.49–1.39 (m, 2H), 1.37–1.19 (m, 10H), 0.91 (t, J = 7.0 Hz, 3H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 156.4, 140.1, 139.5, 128.9, 128.8, 127.2, 126.6, 122.8, 119.6, 85.9, 84.6, 54.6, 49.4, 31.9, 29.8, 29.3, 29.2, 29.0, 28.6, 22.8, 18.8, 14.2. HRMS (ESI) calcd for C₂₇H₃₇N₂O (M + H)⁺ m/z 405.2906, found m/z 405.2908.

1-(2-Methyl-4-phenylbut-3-yn-2-yl)-3-phenylurea (1i). Compound 1i was synthesized according to the general procedure.²⁶ The crude was purified by silica gel column chromatography to obtain 1i with a 78% yield (217 mg) as a yellowish solid; mp (hexane) 182.3–183.7 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.36 (bs, 1H), 7.45–7.30 (m, 7H), 7.23 (t, J = 7.9 Hz, 2H), 6.90 (t, J = 7.3 Hz, 1H), 6.53 (bs, 1H), 1.66 (s, 6H). ¹³C{¹H} NMR (101 MHz, DMSO-*d*₆) δ 153.8, 140.2, 131.2, 128.6, 128.4, 128.1, 122.6, 121.0, 117.5, 94.5, 79.6, 46.6, 29.4. HRMS (ESI) calcd for C₁₈H₁₈N₂NaO (M + Na)⁺ m/z 301.1317, found m/z 301.1313.

1-(2-Methyl-4-(4-(trifluoromethyl)phenyl)but-3-yn-2-yl)-3-phenylurea (1j). Compound 1j was synthesized according to the general procedure.²⁶ The crude was purified by silica gel column chromatography to obtain 1j with a 91% yield (315 mg) as a white solid; mp (hexane) 183.9–185.2 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.38 (bs, 1H), 7.68 (d, J = 8.3 Hz, 2H), 7.58 (d, J = 8.2 Hz, 2H), 7.43 (d, J = 7.6 Hz, 2H), 7.23 (t, J = 7.9 Hz, 2H), 6.90 (t, J = 7.3 Hz, 1H), 6.58 (bs, 1H), 1.68 (s, 6H). ¹³C{¹H} NMR (101 MHz, DMSO-*d*₆) δ 153.9, 140.2, 132.0, 128.6, 128.3 (q, $J_{C,F}$ = 32.1 Hz), 127.1 (q, $J_{C,F}$ = 1.2 Hz), 125.4 (q, $J_{C,F}$ = 3.6 Hz), 124.0 (q, $J_{C,F}$ = 271.9 Hz), 121.2, 117.7, 97.4, 78.5, 46.6, 29.3. ¹⁹F{¹H} NMR (376 MHz, DMSO-*d*₆) δ –61.47. HRMS (ESI) calcd for C₁₉H₁₇F₃N₂NaO (M + Na)⁺ m/z 369.1191, found m/z 369.1194.

1-(4-(4-Methoxyphenyl)-2-methylbut-3-yn-2-yl)-3-phenylurea (1k). Compound 1k was synthesized according to the general procedure.²⁶ The crude was purified by silica gel column chromatography to obtain 1k with 57% yield (176 mg) as pale yellow solid; mp (hexane) 178.2–178.6 °C. ¹H NMR (400 MHz,

DMSO- d_6) δ 8.35 (bs, 1H), 7.41 (d, J = 7.8 Hz, 2H), 7.32 (d, J = 8.7 Hz, 2H), 7.23 (t, J = 7.8 Hz, 2H), 6.95–6.86 (m, 3H), 6.51 (bs, 1H), 3.74 (s, 3H), 1.66 (s, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, DMSO- d_6) δ 159.1, 153.9, 140.3, 132.8, 128.7, 121.1, 117.6, 114.7, 114.1, 93.0, 79.6, 55.1, 46.8, 29.6. HRMS (ESI) calcd for $\text{C}_{19}\text{H}_{20}\text{N}_2\text{NaO}_2$ (M + Na) $^+$ m/z 331.1422, found m/z 331.1424.

1-(2-Methyl-4-(thiophen-2-yl)but-3-yn-2-yl)-3-phenylurea (1l). Compound 1l was synthesized according to the general procedure.²⁶ The crude was purified by silica gel column chromatography to obtain 1l with 94% yield (267 mg) as a yellowish solid; mp (hexane) 210.3–211.4 °C. ^1H NMR (400 MHz, DMSO- d_6) δ 8.36 (bs, 1H), 7.51 (d, J = 4.9 Hz, 1H), 7.41 (d, J = 7.9 Hz, 2H), 7.26–7.18 (m, 3H), 7.04–6.99 (m, 1H), 6.91 (t, J = 7.3 Hz, 1H), 6.55 (bs, 1H), 1.65 (s, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, DMSO- d_6) δ 153.9, 140.2, 131.8, 128.7, 127.7, 127.4, 122.4, 121.2, 117.6, 98.3, 73.1, 46.8, 29.4. HRMS (ESI) calcd for $\text{C}_{16}\text{H}_{16}\text{N}_2\text{NaOS}$ (M+Na) $^+$ m/z 307.0881, found m/z 307.0883.

Ethyl 2-(3-(2-Methylbut-3-yn-2-yl)ureido)acetate (1m). Compound 1m was synthesized according to the general procedure.²⁵ The crude was dried under vacuum and used without purification. Compound 1m was obtained as a white solid; mp (hexane) 83.2–84.8 °C. ^1H NMR (400 MHz, CDCl_3) δ 4.19 (q, J = 7.1 Hz, 2H), 4.01 (s, 2H), 2.42 (s, 1H), 1.59 (s, 6H), 1.27 (t, J = 7.1 Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 171.3, 157.2, 87.5, 70.4, 61.4, 46.9, 42.2, 30.1, 14.3. HRMS (ESI) calcd for $\text{C}_{10}\text{H}_{16}\text{N}_2\text{NaO}_3$ (M + Na) $^+$ m/z 235.1059, found m/z 235.1058.

1-Benzyl-1-(1,3-diphenylprop-2-yn-1-yl)-3-phenylurea (3a). Compound 3a was synthesized according to the general procedure.²⁵ The crude was dried under vacuum and used without purification. Compound 3a was obtained as a yellow solid; mp (hexane) 96.2–97.7 °C. The spectroscopic data of 3a were consistent with literature values.³⁴ ^1H NMR (400 MHz, CDCl_3) δ 7.86–7.81 (m, 2H), 7.54–7.37 (m, 13H), 7.33–7.25 (m, 4H), 7.15 (s, 1H), 7.12–7.03 (m, 1H), 6.59 (bs, 1H), 4.76 (d, J = 17.1 Hz, 1H), 4.57 (d, J = 17.1 Hz, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 155.5, 138.7, 138.0, 137.1, 131.6, 129.1, 128.7, 128.6, 128.5, 128.4, 128.3, 128.2, 128.0, 127.7, 127.0, 123.1, 122.3, 119.7, 86.9, 86.0, 51.3, 48.5. HRMS (ESI) calcd for $\text{C}_{29}\text{H}_{25}\text{N}_2\text{O}$ (M + H) $^+$ m/z 417.1967, found m/z 417.1970.

1-Benzyl-3-phenyl-1-(1-phenylundec-2-yn-1-yl)urea (3b). Compound 3b was synthesized according to the general procedure.²⁵ The crude was dried under vacuum and used without purification. Compound 3b was obtained as an orange oil. ^1H NMR (400 MHz, CDCl_3) δ 7.72 (d, J = 7.5 Hz, 2H), 7.48–7.35 (m, 8H), 7.33–7.12 (m, 4H), 7.03 (t, J = 7.1 Hz, 1H), 6.75 (s, 1H), 6.52 (s, 1H), 4.68 (d, J = 16.8 Hz, 1H), 4.48 (d, J = 16.9 Hz, 1H), 2.35 (t, J = 6.7 Hz, 2H), 1.63–1.52 (m, 2H), 1.51–1.25 (m, 10H), 0.99 (t, J = 6.8 Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 155.5, 138.8, 138.6, 137.4, 128.9, 128.7, 128.6, 128.0, 127.9, 127.6, 127.2, 123.0, 119.7, 87.8, 76.7, 51.1, 48.6, 31.8, 29.2, 29.1, 28.9, 28.5, 22.6, 18.7, 14.1. HRMS (ESI) calcd for $\text{C}_{31}\text{H}_{37}\text{N}_2\text{O}$ (M + H) $^+$ m/z 453.2906, found m/z 453.2909.

1-Butyl-1-(1,3-diphenylprop-2-yn-1-yl)-3-phenylurea (3c). Compound 3c was synthesized according to the general procedure.²⁵ The crude was dried under vacuum and used without purification. Compound 3c was obtained as a yellowish oil. ^1H NMR (400 MHz, CDCl_3) δ 7.69–7.64 (m, 2H), 7.55–7.50 (m, 2H), 7.44–7.33 (m, 8H), 7.32–7.27 (m, 2H), 7.08–7.02 (m, 1H), 6.67 (s, 1H), 6.58 (s, 1H), 3.48–3.30 (m, 2H), 1.87–1.73 (m, 1H), 1.61–1.43 (m, 1H), 1.42–1.26 (m, 2H), 0.91 (t, J = 7.3 Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 154.9, 139.0, 138.1, 131.8, 129.0, 128.8, 128.7, 128.5, 128.2, 127.5, 123.2, 122.6, 120.0, 86.8, 86.1, 51.3, 45.5, 31.5, 20.4, 13.9. HRMS (ESI) calcd for $\text{C}_{26}\text{H}_{27}\text{N}_2\text{O}$ (M + H) $^+$ m/z 383.2123, found m/z 383.2120.

1-(1,3-Diphenylprop-2-yn-1-yl)-3-phenyl-1-(1-phenylethyl)urea (3d). Compound 3d was synthesized according to the general procedure.²⁵ Compound 3d was obtained as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 7.91 (d, J = 7.6 Hz, 2H), 7.79 (d, J = 8.0 Hz, 2H), 7.55–7.45 (m, 4H), 7.45–7.30 (m, 6H), 7.29–7.22 (m, 3H), 7.14 (t, J = 7.8 Hz, 2H), 7.03 (t, J = 7.3 Hz, 1H), 6.92 (bs, 1H), 6.36 (s, 1H), 5.52–5.48 (m, 1H), 1.44 (d, J = 7.1 Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR

(101 MHz, CDCl_3) δ 154.6, 140.9, 138.8, 138.2, 131.6, 129.0, 128.7 (2C), 128.6, 128.45, 128.36, 128.3, 128.1, 127.7, 127.2, 122.9, 119.4, 86.9, 86.5, 52.0, 50.7, 17.2. HRMS (ESI) calcd for $\text{C}_{30}\text{H}_{27}\text{N}_2\text{O}$ (M + H) $^+$ m/z 431.2123, found m/z 431.2121.

1-(1,3-Diphenylprop-2-yn-1-yl)-1-(4-methylbenzyl)-3-phenylurea (3e). Compound 3e was synthesized according to the general procedure.²⁵ Compound 3e was obtained as an orange solid; mp (hexane) 109.8–111.2 °C. ^1H NMR (400 MHz, CDCl_3) δ 7.85 (d, J = 7.5 Hz, 2H), 7.55–7.48 (m, 4H), 7.45 (d, J = 7.2 Hz, 1H), 7.41–7.35 (m, 5H), 7.32–7.29 (m, 4H), 7.26 (d, J = 7.9 Hz, 2H), 7.18 (s, 1H), 7.10–7.04 (m, 1H), 6.67 (bs, 1H), 4.72 (d, J = 16.9 Hz, 1H), 4.52 (d, J = 16.9 Hz, 1H), 2.43 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 155.5, 138.8, 138.0, 137.6, 134.0, 131.6, 129.7, 128.7, 128.6, 128.5, 128.2, 128.1, 127.6, 127.0, 123.0, 122.3, 119.6, 86.8, 86.1, 51.2, 48.1, 21.0. HRMS (ESI) calcd for $\text{C}_{30}\text{H}_{27}\text{N}_2\text{O}$ (M + H) $^+$ m/z 431.2123, found m/z 431.2119.

1-(1,3-Diphenylprop-2-yn-1-yl)-1-(4-fluorobenzyl)-3-phenylurea (3f). Compound 3f was synthesized according to the general procedure.²⁵ Compound 3f was obtained as a light orange solid; mp (hexane) 125.6–126.8 °C. ^1H NMR (400 MHz, CDCl_3) δ 7.76 (d, J = 7.6 Hz, 2H), 7.51–7.45 (m, 4H), 7.44–7.36 (m, 6H), 7.32–7.23 (m, 4H), 7.13–7.04 (m, 3H), 7.00 (s, 1H), 6.53 (bs, 1H), 4.70 (d, J = 17.0 Hz, 1H), 4.54 (d, J = 17.0 Hz, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 162.4 (d, J = 246.7 Hz), 155.4, 138.7, 137.9, 133.0 (d, J = 3.1 Hz), 131.7, 128.9 (d, J = 7.8 Hz), 128.8 (2C), 128.7, 128.4, 127.7, 123.4, 122.3, 119.9, 116.0 (d, J = 21.5 Hz), 87.1, 85.9, 51.5, 48.0. $^{19}\text{F}\{^1\text{H}\}$ NMR (376 MHz, CDCl_3) δ -113.93. HRMS (ESI) calcd for $\text{C}_{29}\text{H}_{24}\text{FN}_2\text{O}$ (M + H) $^+$ m/z 435.1873, found m/z 435.1875.

1-Benzyl-3-phenyl-1-(3-phenyl-1-(p-tolyl)prop-2-yn-1-yl)urea (3g). Compound 3g was synthesized according to the general procedure.²⁵ Compound 3g was obtained as a light yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.68–7.61 (m, 2H), 7.54–7.46 (m, 6H), 7.45–7.37 (m, 5H), 7.33–7.25 (m, 5H), 7.12–7.05 (m, 2H), 6.60 (bs, 1H), 4.78 (d, J = 17.0 Hz, 1H), 4.59 (d, J = 17.1 Hz, 1H), 2.49 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 155.4, 138.8, 138.4, 137.9, 137.2, 131.6, 129.1, 129.0, 128.7, 128.6, 128.5, 128.4, 128.3, 128.0, 127.1, 124.8, 123.1, 122.4, 119.7, 86.8, 86.2, 51.3, 48.5, 21.5. HRMS (ESI) calcd for $\text{C}_{30}\text{H}_{27}\text{N}_2\text{O}$ (M + H) $^+$ m/z 431.2123, found m/z 431.2121.

1-Benzyl-1-(1-(4-methoxyphenyl)-3-phenylprop-2-yn-1-yl)-3-phenylurea (3h). Compound 3h was synthesized according to the general procedure.²⁵ Compound 3h was obtained as a yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.72–7.67 (m, 2H), 7.47–7.40 (m, 6H), 7.39–7.32 (m, 4H), 7.29–7.24 (m, 2H), 7.22–7.18 (m, 2H), 7.07–6.97 (m, 4H), 6.48 (bs, 1H), 4.71 (d, J = 17.0 Hz, 1H), 4.52 (d, J = 17.0 Hz, 1H), 3.86 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 159.6, 155.6, 138.8, 137.3, 131.7, 130.2, 129.2, 129.1, 128.8, 128.6, 128.4, 128.1, 127.2, 123.2, 122.5, 119.8, 114.1, 86.8, 86.4, 55.3, 50.8, 48.5. HRMS (ESI) calcd for $\text{C}_{30}\text{H}_{27}\text{N}_2\text{O}_2$ (M + H) $^+$ m/z 447.2072, found m/z 447.2075.

1-Benzyl-1-(1-(3-chlorophenyl)-3-phenylprop-2-yn-1-yl)-3-phenylurea (3i). Compound 3i was synthesized according to the general procedure.²⁵ Compound 3i was obtained as an orange oil. ^1H NMR (400 MHz, CDCl_3) δ 7.82 (s, 1H), 7.72–7.67 (m, 1H), 7.51–7.44 (m, 6H), 7.42–7.35 (m, 6H), 7.32–7.23 (m, 4H), 7.13 (s, 1H), 7.10–7.05 (m, 1H), 6.62 (bs, 1H), 4.73 (d, J = 17.2 Hz, 1H), 4.53 (d, J = 17.2 Hz, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 155.5, 140.2, 138.5, 136.8, 134.6, 131.6, 130.0, 129.1, 128.8, 128.7, 128.4, 128.3, 128.1, 127.8, 126.9, 125.9, 123.4, 122.0, 120.0, 87.4, 85.2, 50.8, 48.3. HRMS (ESI) calcd for $\text{C}_{29}\text{H}_{24}\text{ClN}_2\text{O}$ (M + H) $^+$ m/z 451.1577, found m/z 451.1578.

1-Benzyl-3-phenyl-1-(3-phenyl-1-(3-vinylphenyl)prop-2-yn-1-yl)urea (3j). Compound 3j was synthesized according to the general procedure.²⁵ Compound 3j was obtained as an orange oil. ^1H NMR (400 MHz, CDCl_3) δ 7.81 (s, 1H), 7.69 (d, J = 7.4 Hz, 1H), 7.50–7.35 (m, 12H), 7.30–7.25 (m, 2H), 7.24–7.21 (m, 2H), 7.09 (bs, 1H), 7.08–7.03 (m, 1H), 6.83 (dd, J = 17.6, 10.9 Hz, 1H), 6.53 (bs, 1H), 5.87 (d, J = 17.6 Hz, 1H), 5.36 (d, J = 11.2 Hz, 1H), 4.73 (d, J = 17.0 Hz, 1H), 4.54 (d, J = 17.1 Hz, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 155.6, 138.7, 138.4, 138.1, 137.1, 136.5, 131.7, 129.2, 129.0,

128.8, 128.6, 128.4, 128.1, 127.2, 127.1, 126.0, 125.8, 123.3, 122.4, 119.8, 114.6, 87.1, 85.9, 51.3, 48.6. HRMS (ESI) calcd for $C_{31}H_{27}N_2O$ ($M + H$)⁺ m/z 443.2123, found m/z 443.2127.

1-Benzyl-1-(1-(2-bromophenyl)-3-phenylprop-2-yn-1-yl)-3-phenylurea (3k). Compound **3k** was synthesized according to the general procedure.²⁵ Compound **3k** was obtained as a yellow solid; mp (hexane) 124.7–126.1 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.97 (dd, $J = 7.7, 1.6$ Hz, 1H), 7.68 (dd, $J = 7.9, 1.2$ Hz, 1H), 7.55–7.51 (m, 2H), 7.41–7.34 (m, 6H), 7.33–7.24 (m, 8H), 7.09 (s, 1H), 7.06–7.01 (m, 1H), 6.59 (bs, 1H), 4.62 (s, 2H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 155.5, 138.8, 137.2, 136.6, 133.6, 131.8, 130.8, 130.1, 129.1, 128.8, 128.7, 128.4, 127.9, 127.6, 126.9, 124.6, 123.1, 122.3, 119.7, 87.0, 85.8, 52.2, 48.3. HRMS (ESI) calcd for $C_{29}H_{24}BrN_2O$ ($M + H$)⁺ m/z 495.1072, found m/z 495.1074.

1-Benzyl-1-(1,3-diphenylprop-2-yn-1-yl)-3-propylurea (3l). Compound **3l** was synthesized according to the general procedure.²⁵ Compound **3l** was isolated as a yellow oil in 45% yield (172 mg). ¹H NMR (300 MHz, CDCl₃) δ 7.70–7.64 (m, 2H), 7.44–7.24 (m, 13H), 6.98 (bs, 1H), 4.54 (d, $J = 17.1$ Hz, 1H), 4.41–4.34 (m, 1H), 4.31 (d, $J = 17.1$ Hz, 1H), 3.26–3.04 (m, 2H), 1.40–1.25 (m, 2H), 0.69 (t, $J = 7.4$ Hz, 3H). ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 158.2, 138.6, 137.9, 131.7, 128.9, 128.7, 128.5, 128.4, 128.1, 127.8, 127.7, 126.9, 122.7, 86.7, 86.56, 51.4, 48.3, 42.8, 23.2, 11.1. HRMS (ESI) calcd for $C_{26}H_{27}N_2O$ ($M + H$)⁺ m/z 383.2123, found m/z 383.2126.

1,3-Dibenzyl-1-(1,3-diphenylprop-2-yn-1-yl)urea (3m). Compound **3m** was synthesized according to the general procedure.²⁵ Compound **3m** was isolated as a yellow oil in 62% yield (267 mg). ¹H NMR (300 MHz, CDCl₃) δ 7.77–7.70 (m, 2H), 7.48–7.30 (m, 12H), 7.28–7.22 (m, 3H), 7.06–7.00 (m, 3H), 4.84 (t, $J = 5.5$ Hz, 1H), 4.63 (d, $J = 17.2$ Hz, 1H), 4.54–4.35 (m, 3H). ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 157.9, 139.1, 138.4, 137.6, 131.7, 128.9, 128.7, 128.5, 128.4, 128.3, 128.1, 127.7, 127.6, 127.1, 127.0, 126.9, 122.6, 86.8, 86.3, 51.5, 48.3, 44.9. HRMS (ESI) calcd for $C_{30}H_{27}N_2O$ ($M + H$)⁺ m/z 431.2123, found m/z 431.2121.

1-Benzyl-3-phenyl-1-(1-phenyl-3-(*p*-tolyl)prop-2-yn-1-yl)urea (3n). Compound **3n** was synthesized according to the general procedure.²⁵ Compound **3n** was obtained as a yellowish solid; mp (hexane) 53.6–54.2 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.79–7.72 (m, 2H), 7.49–7.32 (m, 10H), 7.28–7.23 (m, 2H), 7.21–7.13 (m, 4H), 7.06–6.99 (m, 2H), 6.45 (bs, 1H), 4.71 (d, $J = 17.0$ Hz, 1H), 4.50 (d, $J = 17.0$ Hz, 1H), 2.40 (s, 3H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 155.6, 138.9, 138.8, 138.3, 137.3, 131.7, 129.3, 129.2, 128.9, 128.8, 128.3, 128.2, 127.8, 127.2, 123.2, 119.8, 119.4, 87.2, 85.4, 51.5, 48.7, 21.6. HRMS (ESI) calcd for $C_{30}H_{27}N_2O$ ($M + H$)⁺ m/z 431.2123, found m/z 431.2124.

1-Benzyl-1-(3-(4-chlorophenyl)-1-phenylprop-2-yn-1-yl)-3-phenylurea (3o). Compound **3o** was synthesized according to the general procedure.²⁵ Compound **3o** was obtained as a yellow viscous oil. ¹H NMR (400 MHz, CDCl₃) δ 7.74 (d, $J = 7.5$ Hz, 2H), 7.50–7.29 (m, 12H), 7.28–7.22 (m, 2H), 7.21–7.15 (m, 2H), 7.10–7.00 (m, 2H), 6.44 (bs, 1H), 4.68 (d, $J = 17.1$ Hz, 1H), 4.51 (d, $J = 17.1$ Hz, 1H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 155.6, 138.8, 137.9, 137.2, 134.7, 133.0, 129.3, 128.9, 128.8, 128.4, 128.2, 127.8, 127.1, 123.3, 121.0, 119.9, 87.2, 85.9, 51.4, 48.6. HRMS (ESI) calcd for $C_{29}H_{24}ClN_2O$ ($M + H$)⁺ m/z 451.1577, found m/z 451.1579.

1-Benzyl-1-(3-(4-fluorophenyl)-1-phenylprop-2-yn-1-yl)-3-phenylurea (3p). Compound **3p** was synthesized according to the general procedure.²⁵ Compound **3p** was obtained as a viscous yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.81 (d, $J = 7.5$ Hz, 2H), 7.56–7.35 (m, 10H), 7.33–7.22 (m, 4H), 7.13 (s, 1H), 7.10–7.00 (m, 3H), 6.60 (bs, 1H), 4.74 (d, $J = 17.1$ Hz, 1H), 4.58 (d, $J = 17.1$ Hz, 1H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 162.6 (d, $J_{C,F} = 249.9$ Hz), 155.5, 138.8, 137.9, 137.2, 133.6 (d, $J_{C,F} = 8.4$ Hz), 129.1, 128.7 (2C), 128.2, 127.9, 127.7, 127.0, 123.2, 119.8, 118.5 (d, $J_{C,F} = 3.5$ Hz), 115.6 (d, $J_{C,F} = 22.1$ Hz), 85.8 (2C), 51.2, 48.4. ¹⁹F{¹H} NMR (376 MHz, CDCl₃) δ –110.00. HRMS (ESI) calcd for $C_{29}H_{24}FN_2O$ ($M + H$)⁺ m/z 435.1873, found m/z 435.1872.

4,4-Dimethyl-5-methylene-1-phenylimidazolidin-2-one (2a). Compound **2a** was obtained from **1a** in 1 h, according to the general procedure. The crude was purified by flash column chromatography

using hexane/ethyl acetate (1:1) as eluent to give **2a** (78 mg, 97% yield) as a white solid; mp (hexane) 127.5–130.1 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.48–7.42 (m, 2H), 7.35–7.30 (m, 3H), 6.23 (bs, 1H), 4.03, 3.97 (2 partly overlapping bs, 2H), 1.46 (s, 6H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 157.2, 154.68, 135.2, 129.4, 127.7, 127.6, 79.6, 56.7, 29.9. HRMS (ESI) calcd for $C_{12}H_{15}N_2O$ ($M + H$)⁺ m/z 203.1184, found m/z 203.1182.

4,4-Dimethyl-5-methylene-1-(*p*-tolyl)imidazolidin-2-one (2b). Compound **2b** was obtained from **1b** in 16 h, according to the general procedure. The crude was purified by flash column chromatography using hexane/ethyl acetate (1:1) as eluent to give **2b** (69 mg, 82% yield) as a pale orange solid; mp (hexane) 195.2–197.3 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.27 (d, $J = 8.0$ Hz, 2H), 7.21 (d, $J = 8.3$ Hz, 2H), 5.83 (bs, 1H), 4.02 (d, $J = 2.1$ Hz, 1H), 3.97 (d, $J = 2.3$ Hz, 1H), 2.39 (s, 3H), 1.48 (s, 6H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 157.3, 154.9, 137.6, 132.5, 130.1, 127.6, 79.5, 56.7, 29.9, 21.3. HRMS (ESI) calcd for $C_{13}H_{17}N_2O$ ($M + H$)⁺ m/z 217.1341, found m/z 217.1344.

1-(4-Fluorophenyl)-4,4-dimethyl-5-methyleneimidazolidin-2-one (2c). Compound **2c** was obtained from **1c** in 1 h and 30 min, according to the general procedure. The crude was purified by flash column chromatography using hexane/ethyl acetate (1:1) as eluent to give **2c** (86 mg, 97% yield) as an orange solid; mp (hexane) 165.6–167.0 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.33–7.25 (m, 2H), 7.17–7.08 (m, 2H), 5.89 (bs, 1H), 4.03, 3.97 (2 bs, 2H), 1.46 (s, 6H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 161.7 (d, $J_{C,F} = 247.1$ Hz), 157.1, 154.7, 131.1 (d, $J_{C,F} = 3.1$ Hz), 129.6 (d, $J_{C,F} = 8.6$ Hz), 116.4 (d, $J_{C,F} = 22.8$ Hz), 79.9, 56.8, 29.9. ¹⁹F{¹H} NMR (376 MHz, CDCl₃) δ –113.93. HRMS (ESI) calcd for $C_{12}H_{14}FN_2O$ ($M + H$)⁺ m/z 221.1090, found m/z 221.1086.

Methyl 4-(4,4-Dimethyl-5-methylene-2-oxoimidazolidin-1-yl)benzoate (2d). Compound **2d** was obtained from **1d** in 6 h, according to the general procedure. The crude was purified by flash column chromatography using hexane/ethyl acetate (1:1) as eluent to give **2d** (102 mg, 98% yield) as a yellowish solid; mp (hexane) 218.0–220.3 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.14–8.07 (m, 2H), 7.48–7.40 (m, 2H), 6.34 (bs, 1H), 4.17 (dd, $J = 2.6, 0.8$ Hz, 1H), 4.04 (d, $J = 2.6$ Hz, 1H), 3.91 (s, 3H), 1.45 (s, 6H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 166.5, 156.6, 153.5, 139.6, 130.7, 128.6, 127.0, 80.6, 56.8, 52.3, 29.8. HRMS (ESI) calcd for $C_{14}H_{17}N_2O_3$ ($M + H$)⁺ m/z 261.1240, found m/z 261.1242.

4,4-Diethyl-5-methylene-1-phenylimidazolidin-2-one (2e). Compound **2e** was obtained from **1e** in 3 h, according to the general procedure. The crude was purified by flash column chromatography using hexane/ethyl acetate (1:1) as eluent to give **2e** (92 mg, 99% yield) as a pale orange solid; mp (hexane) 120.5–122.2 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.48–7.42 (m, 2H), 7.36–7.31 (m, 1H), 7.30–7.27 (m, 2H), 5.32 (bs, 1H), 4.13 (dd, $J = 2.3, 0.8$ Hz, 1H), 3.87 (d, $J = 2.3$ Hz, 1H), 1.75–1.57 (m, 4H), 0.97 (t, $J = 7.3$ Hz, 6H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 157.9, 150.9, 135.2, 129.5, 127.8, 127.7, 80.2, 63.6, 34.1, 7.8. HRMS (ESI) calcd for $C_{14}H_{19}N_2O$ ($M + H$)⁺ m/z 231.1497, found m/z 231.1499.

4-Methylene-3-phenyl-1,3-diazaspiro[4.5]decan-2-one (2f). Compound **2f** was obtained from **1f** in 16 h, according to the general procedure. The crude was purified by flash column chromatography using hexane/ethyl acetate (1:1) as eluent to give **2f** (92 mg, 95% yield) as a white solid; mp (hexane) 175.2–176.7 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.47–7.41 (m, 2H), 7.34–7.29 (m, 3H), 6.07 (bs, 1H), 4.07 (d, $J = 2.3$ Hz, 1H), 3.96 (d, $J = 2.3$ Hz, 1H), 1.92–1.83 (m, 2H), 1.81–1.70 (m, 2H), 1.63–1.53 (m, 2H), 1.49–1.35 (m, 2H), 1.35–1.21 (m, 2H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 157.2, 154.5, 135.1, 129.4, 127.7, 127.6, 80.2, 59.5, 38.6, 25.0, 22.4. HRMS (ESI) calcd for $C_{13}H_{19}N_2O$ ($M + H$)⁺ m/z 243.1497, found m/z 243.1500.

3-Benzyl-4,4-dimethyl-5-methylene-1-phenylimidazolidin-2-one (2g). Compound **2g** was obtained from **1g** in 16 h, according to the general procedure. The crude was purified by flash column chromatography using hexane/ethyl acetate (7:3) as eluent to give **2g** (61 mg, 52% yield) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.47 (d, $J = 7.2$ Hz, 2H), 7.39–7.25 (m, 5H), 7.20–7.16 (m, 2H),

7.06–7.00 (m, 1H), 4.64 (d, $J = 3.3$ Hz, 1H), 4.63 (s, 2H), 4.20 (d, $J = 3.3$ Hz, 1H), 1.36 (s, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 162.8, 149.2, 147.0, 139.0, 128.6, 128.5, 127.8, 127.3, 123.8, 122.3, 83.3, 61.1, 44.4, 27.6. HRMS (ESI) calcd for $\text{C}_{19}\text{H}_{21}\text{N}_2\text{O}$ ($\text{M} + \text{H}^+$) m/z 293.1654, found m/z 293.1652.

3-Benzyl-4,4-dimethyl-5-nonylidene-1-phenylimidazolidin-2-one (2h). Compound **2h** was obtained from **1h** in 16 h, according to the general procedure. The crude was purified by flash column chromatography using hexane/ethyl acetate (7:3) as eluent to give a mixture of *E* and *Z* (150 mg, 83%) in a ca. 1:0.06 molar ratio. The major *Z* isomer was characterized as follows: ^1H NMR (400 MHz, CDCl_3) δ 7.45–7.40 (m, 4H), 7.38–7.30 (m, 5H), 7.30–7.26 (m, 1H), 4.54 (s, 2H), 4.34 (t, $J = 7.3$ Hz, 1H), 1.47–1.41 (m, 2H), 1.35 (s, 6H), 1.32–1.27 (m, 2H), 1.25–1.04 (m, 10H), 0.91 (t, $J = 7.1$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 157.4, 143.3, 139.6, 138.1, 128.7, 128.5, 127.9, 127.7, 127.2, 126.9, 99.4, 61.1, 43.4, 31.9, 30.0, 29.3, 29.2, 29.0, 27.9, 26.1, 22.7, 14.1. HRMS (ESI) calcd for $\text{C}_{27}\text{H}_{37}\text{N}_2\text{O}$ ($\text{M} + \text{H}^+$) m/z 405.2906, found m/z 405.2904.

5-Benzylidene-4,4-dimethyl-1-phenylimidazolidin-2-one (2i). Compound **2i** was obtained from **1i** in 16 h, according to the general procedure. The crude was purified by flash column chromatography using hexane/ethyl acetate (1:1) as eluent to give two fractions, one containing the pure **2i** *Z* isomer (62 mg), the other containing a mixture of *E* and *Z* (**35** mg; see ^1H NMR spectrum of the mixture in the SI). The overall yield of *Z* and *E* isomers of **2i** amounted to 87% (97 mg) with *Z/E* isomers in a 1:0.25 molar ratio. The major isomer *Z* was isolated as a yellowish solid (mp from hexane: 216.5–217.8 °C) and characterized as follows: ^1H NMR (400 MHz, CDCl_3) δ 7.06–6.95 (m, 5H), 6.88–6.80 (m, 3H), 6.68 (dd, $J = 7.2$, 1.9 Hz, 2H), 5.81 (bs, 1H), 5.59 (s, 1H), 1.57 (s, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 157.8, 145.0, 135.9, 134.6, 128.3, 128.1, 127.0, 126.2, 126.1, 125.2, 99.0, 57.6, 30.1. HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{19}\text{N}_2\text{O}$ ($\text{M} + \text{H}^+$) m/z 279.1497, found m/z 279.1498.

4,4-Dimethyl-1-phenyl-5-(4-(trifluoromethyl)benzylidene)imidazolidin-2-one (2j). Compound **2j** was obtained from **1j** in 4 h, according to the general procedure. The crude was purified by flash column chromatography using hexane/ethyl acetate (1:1) as eluent to give two fractions, one containing the pure **2j** *Z* isomer (85 mg), the other containing a mixture of *E* and *Z* (43 mg; see ^1H NMR spectrum of the mixture in the SI). The overall yield of *Z* and *E* isomers of **2j** amounted to 93% (128 mg) with *Z/E* isomers in a 1:0.3 molar ratio. The major isomer *Z* was isolated as a white solid (mp from hexane: 208.5–211.4 °C) and characterized as follows: ^1H NMR (400 MHz, CDCl_3) δ 7.54–7.47 (m, 4H), 7.41–7.34 (m, 3H), 7.29 (d, $J = 8.6$ Hz, 2H), 5.61 (s, 1H), 5.49 (bs, 1H), 1.42 (s, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 156.7, 149.5, 140.1 (q, $J_{\text{C,F}} = 0.9$ Hz), 134.9, 130.3, 129.8, 128.6 (q, $J_{\text{C,F}} = 29.5$ Hz), 128.5, 128.3, 125.0 (q, $J_{\text{C,F}} = 3.8$ Hz), 124.3 (q, $J_{\text{C,F}} = 271.8$ Hz), 99.9, 57.8, 29.2. $^{19}\text{F}\{^1\text{H}\}$ NMR (376 MHz, CDCl_3) δ –62.44. HRMS (ESI) calcd for $\text{C}_{19}\text{H}_{18}\text{F}_3\text{N}_2\text{O}$ ($\text{M} + \text{H}^+$) m/z 347.1371, found m/z 347.1369.

5-(4-Methoxybenzylidene)-4,4-dimethyl-1-phenylimidazolidin-2-one (2k). Compound **2k** was obtained from **1k** in 16 h, according to the general procedure. The crude was purified by flash column chromatography using hexane/ethyl acetate (1:1) as eluent to give two fractions, one containing the pure **2k** *Z* isomer (32 mg), the other containing a mixture of *E* and *Z* (71 mg; see ^1H NMR spectrum of the mixture in the SI). The overall yield of *Z* and *E* isomers of **2k** amounted to 84% (103 mg) with *Z/E* isomers in a 1:0.04 molar ratio. The major isomer *Z* was isolated as a white solid (mp from hexane: 182.4–184.7 °C) and characterized as follows: ^1H NMR (400 MHz, CDCl_3) δ 7.08–6.96 (m, 5H), 6.59 (d, $J = 8.7$ Hz, 2H), 6.39 (d, $J = 8.7$ Hz, 2H), 5.92 (bs, 1H), 5.54 (s, 1H), 3.65 (s, 3H), 1.55 (s, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 157.9, 157.3, 143.9, 135.9, 129.3, 128.0, 127.2, 126.1, 126.0, 112.6, 98.7, 57.5, 55.3, 30.1. HRMS (ESI) calcd for $\text{C}_{19}\text{H}_{21}\text{N}_2\text{O}_2$ ($\text{M} + \text{H}^+$) m/z 309.1603, found m/z 309.1607.

4,4-Dimethyl-1-phenyl-5-(thiophen-2-ylmethylene)imidazolidin-2-one (2l). Compound **2l** was obtained from **1l** in 1 h and 30 min, according to the general procedure. The crude was purified by flash column chromatography using hexane/ethyl acetate (1:1) as eluent to

give a mixture of *E* and *Z* (110 mg, 97%) in a 1:0.8 molar ratio. *E* and *Z* isomers were characterized as follows: ^1H NMR (400 MHz, CDCl_3) δ 7.51–7.46 (m, 1H(*Z*) + 1H(*E*)), 7.43–7.31 (m, 3H), 7.19–7.06 (m, 6H), 6.96–6.85 (m, 1H(*Z*) + 1H(*E*)), 6.77 (d, $J = 3.4$ Hz, 1H), 6.48 (dd, $J = 5.0$, 3.7 Hz, 1H), 6.13 (bs, 1H), 6.01 (bs, 1H), 5.98 (d, $J = 3.5$ Hz, 1H), 5.57 (s, 1H(*E*)), 5.51 (s, 1H(*Z*)), 1.57 (s, 6H(*Z*)), 1.55 (s, 6H(*E*)). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 157.6, 156.8, 150.1, 145.6, 137.5, 136.8, 135.7, 134.9, 129.7, 128.7, 128.2, 127.3, 126.8, 126.6, 126.5, 126.5, 126.3, 124.8, 123.8, 93.1, 91.5, 57.9, 57.7, 29.9, 28.4. HRMS (ESI) calcd for $\text{C}_{16}\text{H}_{17}\text{N}_2\text{OS}$ ($\text{M} + \text{H}^+$) m/z 285.1061, found m/z 285.1063.

3-(2-Methylbut-3-yn-2-yl)imidazolidin-2,4-dione (2m'). Compound **2m'** was obtained from **1m** in 16 h at 50 °C, according to the general procedure. The crude was purified by flash column chromatography using hexane/ethyl acetate (1:1) as eluent to give **2m'** (48 mg, 72% yield) as a white solid; mp (hexane) 81.1–82.6 °C. ^1H NMR (400 MHz, CDCl_3) δ 6.33 (bs, 1H), 3.88 (d, $J = 1.2$ Hz, 2H), 2.47 (s, 1H), 1.89 (s, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 170.9, 158.1, 85.5, 71.2, 52.3, 46.2, 29.0. HRMS (ESI) calcd for $\text{C}_8\text{H}_{11}\text{N}_2\text{O}_2$ ($\text{M} + \text{H}^+$) m/z 167.0820, found m/z 167.0817.

(Z)-N-(4,4-Dimethyl-5-methylenethiazolidin-2-ylidene)-4-fluoroaniline (2n'). Compound **2n'** was synthesized as reported above, in the absence of catalyst.²⁵ Expected acyclic thiourea **1i** was not detected, and (Z)-N-(4,4-dimethyl-5-methylenethiazolidin-2-ylidene)-4-fluoroaniline (**2n'**) was instead isolated. Product **2n'** was recovered without purification in 98% yield (1 mmol, 231 mg) as a yellow solid; mp (hexane) 223.3–224.6 °C. ^1H NMR (400 MHz, $\text{DMSO}-d_6$, recorded at 80 °C) δ 8.73 (bs, 1H), 7.54–7.32 (m, 2H), 7.16–6.88 (m, 2H), 5.21 (d, $J = 1.4$ Hz, 1H), 5.14 (d, $J = 1.4$ Hz, 1H), 1.42 (s, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, $\text{DMSO}-d_6$, recorded at 80 °C) δ 157.0 (d, $J_{\text{C,F}} = 238.3$ Hz), 154.7, 149.5, 139.8, 120.0 (d, $J_{\text{C,F}} = 7.1$ Hz), 114.6 (d, $J_{\text{C,F}} = 22.2$ Hz), 101.6, 74.4, 29.5. $^{19}\text{F}\{^1\text{H}\}$ NMR (376 MHz, $\text{DMSO}-d_6$) δ –121.82. HRMS (ESI) calcd for $\text{C}_{12}\text{H}_{13}\text{FN}_2\text{NaS}$ ($\text{M} + \text{Na}^+$) m/z 259.0681, found m/z 259.0683.

1,4-Dibenzyl-3,5-diphenyl-1H-imidazol-2(3H)-one (4a). Compound **4a** was obtained from **3a** in 1 min, according to the general procedure. The crude was purified by flash column chromatography using hexane/ethyl acetate (6:4) as eluent to give **4a** (139 mg, 83% yield) as a pale yellow oil. The spectroscopic data of **4a** were consistent with literature values.^{8a} ^1H NMR (400 MHz, CDCl_3) δ 7.43–7.36 (m, 3H), 7.35–7.23 (m, 8H), 7.20–7.15 (m, 2H), 7.14–7.08 (m, 5H), 6.81–6.72 (m, 2H), 4.92 (s, 2H), 3.71 (s, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 153.6, 138.2, 137.9, 135.2, 130.4, 129.1, 129.0, 128.7, 128.6, 128.5, 128.2, 128.1, 128.0, 127.8, 127.8, 127.3, 126.3, 122.3, 119.1, 45.5, 29.8. HRMS (ESI) calcd for $\text{C}_{29}\text{H}_{25}\text{N}_2\text{O}$ ($\text{M} + \text{H}^+$) m/z 417.1967, found m/z 417.1970.

1-Benzyl-4-nonyl-3,5-diphenyl-1H-imidazol-2(3H)-one (4b). Compound **4b** was obtained from **3b** in 1 min, according to the general procedure. After 16 h, the yield of **4b** did not improve and most of the starting material was recovered (70%). The crude was purified by flash column chromatography using hexane/ethyl acetate (7:3) as eluent to give **4b** (33 mg, 18% yield) as a pale orange oil. ^1H NMR (400 MHz, CDCl_3) δ 7.50–7.45 (m, 2H), 7.42–7.40 (m, 1H), 7.40–7.38 (m, 1H), 7.38–7.34 (m, 4H), 7.23–7.15 (m, 5H), 7.06–7.02 (m, 2H), 4.81 (s, 2H), 2.35–2.31 (m, 2H), 1.27–0.90 (m, 14H), 0.85 (t, $J = 7.2$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 153.5, 138.0, 135.7, 130.6, 129.5, 129.3, 128.6, 128.4, 128.4, 127.9, 127.8 (2C), 127.3, 121.1, 120.8, 45.4, 31.9, 29.3, 29.2, 28.9, 28.7, 28.4, 23.5, 22.7, 14.2. HRMS (ESI) calcd for $\text{C}_{31}\text{H}_{37}\text{N}_2\text{O}$ ($\text{M} + \text{H}^+$) m/z 453.2906, found m/z 453.2902.

4-Benzyl-1-butyl-3,5-diphenyl-1H-imidazol-2(3H)-one (4c). Compound **4c** was obtained from **3c** in 1 min, according to the general procedure. The crude was purified by flash column chromatography using hexane/ethyl acetate (7:3) as eluent to give **4c** (108 mg, 71% yield) as a white solid; mp (hexane) 112.6–113.7 °C. ^1H NMR (400 MHz, CDCl_3) δ 7.48–7.36 (m, 5H), 7.31–7.23 (m, 3H), 7.14–7.05 (m, 5H), 6.73 (dd, $J = 6.6$, 2.8 Hz, 2H), 3.75–3.70 (m, 2H), 3.68 (s, 2H), 1.56–1.47 (m, 2H), 1.28–1.17 (m, 2H), 0.81 (t, $J = 7.4$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 153.2, 138.3, 135.2, 130.0, 129.4, 128.9, 128.8, 128.5, 128.2, 128.0, 127.9,

127.7, 126.2, 122.2, 118.7, 41.5, 31.3, 29.7, 19.8, 13.6. HRMS (ESI) calcd for $C_{22}H_{27}N_2O$ ($M + H$)⁺ m/z 383.2123, found m/z 383.2126.

4-Benzyl-3,5-diphenyl-1-(1-phenylethyl)-1H-imidazol-2(3H)-one (4d). Compound **4d** was obtained from **3d** in 1 min, according to the general procedure. The crude was purified by flash column chromatography using hexane/ethyl acetate (6:4) as eluent to give **4d** (160 mg, 93% yield) as pale orange oil. ¹H NMR (400 MHz, CDCl₃) δ 7.40–7.35 (m, 3H), 7.35–7.26 (m, 8H), 7.24–7.20 (m, 2H), 7.15 (dd, $J = 7.9, 1.4$ Hz, 2H), 7.13–7.08 (m, 3H), 6.74 (dd, $J = 6.4, 2.6$ Hz, 2H), 5.29 (q, $J = 7.2$ Hz, 1H), 3.72–3.56 (m, 2H), 1.86 (d, $J = 7.2$ Hz, 3H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 153.1, 141.7, 138.2, 135.0, 131.0, 129.3, 128.8, 128.6, 128.5, 128.3, 128.1, 128.0, 127.9, 127.6, 127.1, 127.0, 126.2, 122.3, 119.0, 53.0, 29.8, 18.6. HRMS (ESI) calcd for $C_{30}H_{27}N_2O$ ($M + H$)⁺ m/z 431.2123, found m/z 431.2120.

4-Benzyl-1-(4-methylbenzyl)-3,5-diphenyl-1H-imidazol-2(3H)-one (4e). Compound **4e** was obtained from **3e** in 1 min, according to the general procedure. The crude was purified by flash column chromatography using hexane/ethyl acetate (6:4) as eluent to give **4e** (156 mg, 91% yield) as an orange solid; mp (hexane) 146.3–148.1 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.41–7.36 (m, 3H), 7.35–7.27 (m, 5H), 7.18–7.14 (m, 2H), 7.12–7.04 (m, 5H), 7.01 (d, $J = 8.1$ Hz, 2H), 6.75 (dd, $J = 6.3, 2.7$ Hz, 2H), 4.88 (s, 2H), 3.70 (s, 2H), 2.32 (s, 3H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 153.5, 138.2, 136.8, 135.1, 134.9, 130.4, 129.1 (2C), 128.9, 128.7, 128.5, 128.2, 128.0, 127.9, 127.8, 127.7, 126.2, 122.3, 119.0, 45.2, 29.7, 21.1. HRMS (ESI) calcd for $C_{30}H_{27}N_2O$ ($M + H$)⁺ m/z 431.2123, found m/z 431.2121.

4-Benzyl-1-(4-fluorobenzyl)-3,5-diphenyl-1H-imidazol-2(3H)-one (4f). Compound **4f** was obtained from **3f** in 1 min, according to the general procedure. The crude was purified by flash column chromatography using hexane/ethyl acetate (6:4) as eluent to give **4f** (161 mg, 93% yield) as a dark yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.42–7.38 (m, 3H), 7.35–7.24 (m, 5H), 7.15 (dd, $J = 7.7, 1.4$ Hz, 2H), 7.12–7.03 (m, 5H), 6.93 (t, $J = 8.7$ Hz, 2H), 6.72 (dd, $J = 6.2, 2.7$ Hz, 2H), 4.86 (s, 2H), 3.69 (s, 2H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 162.05 (d, $J_{C,F} = 245.5$ Hz), 153.4, 138.0, 135.0, 133.6 (d, $J_{C,F} = 3.2$ Hz), 130.3, 129.6 (d, $J_{C,F} = 8.1$ Hz), 128.9, 128.7, 128.6, 128.2, 128.0, 127.9, 127.8, 126.2, 122.0, 119.2, 115.20 (d, $J_{C,F} = 21.4$ Hz), 44.7, 29.7. ¹⁹F{¹H} NMR (376 MHz, CDCl₃) δ –115.09. HRMS (ESI) calcd for $C_{29}H_{24}FN_2O$ ($M + H$)⁺ m/z 435.1873, found m/z 435.1875.

1,4-Bibenzyl-3-phenyl-5-(p-tolyl)-1H-imidazol-2(3H)-one (4g). Compound **4g** was obtained from **3g** in 1 min, according to the general procedure. The crude was purified by flash column chromatography using hexane/ethyl acetate (6:4) as eluent to give **4g** (144 mg, 84% yield) as a dark yellow solid; mp (hexane) 125.8–127.3 °C. The spectroscopic data of **4g** were consistent with literature values.³⁵ ¹H NMR (400 MHz, CDCl₃) δ 7.37–7.26 (m, 7H), 7.23–7.15 (m, 5H), 7.15–7.10 (m, 4H), 7.07 (s, 1H), 6.79 (dd, $J = 6.7, 2.3$ Hz, 2H), 4.93 (s, 2H), 3.74 (s, 2H), 2.34 (s, 3H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 153.5, 138.2, 138.0, 135.2, 131.1, 129.3, 128.9, 128.5, 128.4, 128.1, 128.0, 127.9, 127.8, 127.7, 127.4, 127.2, 126.2, 122.5, 118.8, 45.5, 29.7, 21.3. HRMS (ESI) calcd for $C_{30}H_{27}N_2O$ ($M + H$)⁺ m/z 431.2123, found m/z 431.2120.

1,4-Dibenzyl-5-(4-methoxyphenyl)-3-phenyl-1H-imidazol-2(3H)-one (4h). Compound **4h** was obtained from **3h** in 1 min, according to the general procedure. The crude was purified by flash column chromatography using hexane/ethyl acetate (6:4) as eluent to give **4h** (137 mg, 77% yield) as a white solid; mp (hexane) 166.6–168.3 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.37–7.24 (m, 6H), 7.24–7.15 (m, 6H), 7.15–7.09 (m, 3H), 6.95–6.89 (m, 2H), 6.79 (dd, $J = 7.1, 2.2$ Hz, 2H), 4.91 (s, 2H), 3.82 (s, 3H), 3.71 (s, 2H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 159.7, 153.3, 138.2, 137.9, 135.1, 131.7, 128.8, 128.3, 128.1, 127.9, 127.8, 127.6 (2C), 127.1, 126.1, 121.9, 121.0, 118.6, 114.0, 55.2, 45.3, 29.6. HRMS (ESI) calcd for $C_{30}H_{27}N_2O_2$ ($M + H$)⁺ m/z 447.2072, found m/z 447.2074.

1,4-Dibenzyl-5-(3-chlorophenyl)-3-phenyl-1H-imidazol-2(3H)-one (4i). Compound **4i** was obtained from **3i** in 1 min, according to the general procedure. The crude was purified by flash column chromatography using hexane/ethyl acetate (6:4) as eluent to give **4i**

(155 mg, 86% yield) as an orange solid; mp (hexane) 130.5–132.7 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.38–7.25 (m, 8H), 7.22 (t, $J = 1.4$ Hz, 1H), 7.18–7.09 (m, 8H), 6.73 (dd, $J = 6.5, 2.4$ Hz, 2H), 4.89 (s, 2H), 3.69 (s, 2H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 153.4, 137.6, 137.5, 134.8, 134.4, 130.7, 130.2, 129.9, 128.9, 128.6, 128.4, 128.3, 128.2, 127.9, 127.8, 127.7, 127.6, 127.3, 126.3, 120.9, 119.7, 45.5, 29.6. HRMS (ESI) calcd for $C_{29}H_{24}ClN_2O$ ($M + H$)⁺ m/z 451.1577, found m/z 451.1581.

1,4-Dibenzyl-3-phenyl-5-(3-vinylphenyl)-1H-imidazol-2(3H)-one (4j). Compound **4j** was obtained from **3j** in 1 min, according to the general procedure. The crude was purified by flash column chromatography using hexane/ethyl acetate (6:4) as eluent to give **4j** (133 mg, 75% yield) as a pale yellow solid; mp (hexane) 143.8–145.2 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.43 (d, $J = 7.8$ Hz, 1H), 7.38–7.32 (m, 4H), 7.32–7.26 (m, 4H), 7.23–7.16 (m, 5H), 7.15–7.11 (m, 3H), 6.80 (dd, $J = 6.8, 2.2$ Hz, 2H), 6.66 (dd, $J = 17.6, 10.9$ Hz, 1H), 5.62 (d, $J = 17.6$ Hz, 1H), 5.27 (d, $J = 10.9$ Hz, 1H), 4.93 (s, 2H), 3.74 (s, 2H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 153.6, 138.2, 138.02, 137.97, 136.1, 135.1, 129.6, 129.3, 129.0, 128.9, 128.5, 128.3, 128.14, 128.08, 127.97, 127.85, 127.77, 127.3, 126.5, 126.3, 122.2, 119.1, 114.8, 45.7, 29.8. HRMS (ESI) calcd for $C_{31}H_{27}N_2O$ ($M + H$)⁺ m/z 443.2123, found m/z 443.2120.

1,4-Dibenzyl-5-(2-bromophenyl)-3-phenyl-1H-imidazol-2(3H)-one (4k). Compound **4k** was obtained from **3k** in 1 min, according to the general procedure. The crude was purified by flash column chromatography using hexane/ethyl acetate (7:3) as eluent to give **4k** (134 mg, 68% yield) as a dark yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.68 (dd, $J = 7.3, 1.8$ Hz, 1H), 7.39–7.31 (m, 3H), 7.30–7.19 (m, 7H), 7.14 (dd, $J = 6.7, 2.5$ Hz, 1H), 7.10–7.06 (m, 3H), 7.05–7.01 (m, 2H), 6.79 (dd, $J = 6.4, 2.7$ Hz, 2H), 5.12 (d, $J = 15.2$ Hz, 1H), 4.60 (d, $J = 15.2$ Hz, 1H), 3.71–3.52 (m, 2H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 153.1, 137.5, 137.4, 135.0, 133.8, 132.9, 130.7, 130.1, 128.9, 128.2, 128.1, 128.1, 128.0, 127.9, 127.8, 127.3, 127.2, 126.4, 126.1, 120.4, 119.7, 45.6, 30.0. HRMS (ESI) calcd for $C_{29}H_{24}BrN_2O$ ($M + H$)⁺ m/z 495.1072, found m/z 495.1071.

1,4-Dibenzyl-5-phenyl-3-propyl-1H-imidazol-2(3H)-one (4l). Compound **4l** was obtained from **3l** in 1 min, according to the general procedure. After 16 h, the yield remain unchanged and 42% of the starting material was recovered. The crude was purified by flash column chromatography using hexane/ethyl acetate (6:4) as eluent to give **4l** (50 mg, 33% yield) as a yellowish oil. ¹H NMR (400 MHz, CDCl₃) δ 7.34–7.28 (m, 5H), 7.27–7.21 (m, 4H), 7.20–7.16 (m, 2H), 7.15–7.11 (m, 2H), 7.05 (dd, $J = 7.8, 1.6$ Hz, 2H), 4.87 (s, 2H), 3.81 (s, 2H), 3.48–3.43 (m, 2H), 1.60–1.49 (m, 2H), 0.85 (t, $J = 7.4$ Hz, 3H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 154.0, 138.4, 138.2, 130.2, 129.2, 128.8, 128.6, 128.4, 128.3, 127.8, 127.4, 127.2, 126.8, 121.7, 118.1, 45.4, 43.45, 29.6, 22.8, 11.3. HRMS (ESI) calcd for $C_{26}H_{27}N_2O$ ($M + H$)⁺ m/z 383.2123, found m/z 383.2127.

1,3,4-tribenzyl-5-phenyl-1H-imidazol-2(3H)-one (4m). Compound **4m** was obtained from **3m** in 1 min, according to the general procedure. The crude was purified by flash column chromatography using hexane/ethyl acetate (6:4) as eluent to give **4m** (144 mg, 84% yield) as a yellow oil. Spectroscopic data of **4m** were consistent with literature values.³⁴ ¹H NMR (400 MHz, CDCl₃) δ 7.37–7.25 (m, 12H), 7.24–7.18 (m, 4H), 7.14–7.07 (m, 4H), 4.96 (s, 2H), 4.72 (s, 2H), 3.65 (s, 2H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 154.4, 138.1, 138.0, 137.9, 130.1, 129.0, 128.9, 128.7, 128.6, 128.5, 128.4, 127.8, 127.4, 127.3, 127.2, 127.1, 126.8, 122.2, 118.0, 45.6, 44.9, 29.5. HRMS (ESI) calcd for $C_{30}H_{27}N_2O$ ($M + H$)⁺ m/z 431.2123, found m/z 431.2125.

1-Benzyl-4-(4-methylbenzyl)-3,5-diphenyl-1H-imidazol-2(3H)-one (4n). Compound **4n** was obtained from **3n** in 1 min, according to the general procedure. The crude was purified by flash column chromatography using hexane/ethyl acetate (6:4) as eluent to give **4n** (139 mg, 81% yield) as a yellow solid; mp (hexane) 128.4–129.4 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.45–7.33 (m, 6H), 7.32–7.25 (m, 5H), 7.24–7.18 (m, 2H), 7.18–7.11 (m, 2H), 6.94 (d, $J = 7.9$ Hz, 2H), 6.66 (d, $J = 7.9$ Hz, 2H), 4.93 (s, 2H), 3.68 (s, 2H), 2.28 (s, 3H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 153.6, 137.9, 135.7, 135.1, 130.3, 129.1, 129.0, 128.9, 128.7, 128.5, 128.4, 128.1, 127.8 (2C),

127.7, 127.3, 122.1, 119.2, 45.5, 29.2, 21.0. HRMS (ESI) calcd for $C_{30}H_{27}N_2O$ ($M + H$)⁺ m/z 431.2123, found m/z 431.2122.

1-Benzyl-4-(4-chlorobenzyl)-3,5-diphenyl-1H-imidazol-2(3H)-one (4o). Compound **4o** was obtained from **3o** in 1 min, according to the general procedure. The crude was purified by flash column chromatography using hexane/ethyl acetate (7:3) as eluent to give **4o** (176 mg, 98% yield) as a viscous light yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.42–7.30 (m, 6H), 7.29–7.22 (m, 5H), 7.19 (d, $J = 7.3$ Hz, 2H), 7.14–7.03 (m, 4H), 6.66 (d, $J = 8.3$ Hz, 2H), 4.91 (s, 2H), 3.67 (s, 2H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 153.5, 137.8, 136.7, 135.1, 132.0, 130.3, 129.3, 129.1, 128.9, 128.8, 128.7, 128.4, 128.3, 128.0, 127.9, 127.8, 127.3, 122.5, 118.5, 45.5, 29.2. HRMS (ESI) calcd for $C_{29}H_{24}ClN_2O$ ($M + H$)⁺ m/z 451.1577, found m/z 451.1576.

1-Benzyl-4-(4-fluorobenzyl)-3,5-diphenyl-1H-imidazol-2(3H)-one (4p). Compound **4p** was obtained from **3p** in 1 min, according to the general procedure. The crude was purified by flash column chromatography using hexane/ethyl acetate (7:3) as eluent to give **4p** (168 mg, 97% yield) as a viscous oil. ¹H NMR (400 MHz, CDCl₃) δ 7.43–7.23 (m, 11H), 7.22–7.17 (m, 2H), 7.15–7.10 (m, 2H), 6.82–6.75 (m, 2H), 6.72–6.65 (m, 2H), 4.93 (s, 2H), 3.69 (s, 2H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 161.3 (d, $J_{C,F} = 244.6$ Hz), 153.4, 137.8, 135.1, 133.7 (d, $J_{C,F} = 3.2$ Hz), 130.3, 129.3 (d, $J_{C,F} = 7.9$ Hz), 129.0, 128.9, 128.7, 128.6, 128.3, 127.9, 127.8, 127.7, 127.2, 122.3, 118.9, 114.9 (d, $J_{C,F} = 21.3$ Hz), 45.4, 28.9. ¹⁹F{¹H} NMR (376 MHz, CDCl₃) δ –116.60. HRMS (ESI) calcd for $C_{29}H_{24}FN_2O$ ($M + H$)⁺ m/z 435.1873, found m/z 435.1874.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.9b00064.

Copy of NMR spectra, computational details and single crystal X-ray diffraction data for **2a**, **2i** (Z), **2n'**, **4c**, and **4j** (PDF)

■ AUTHOR INFORMATION

Corresponding Authors

*E-mail: stirling.andras@ttk.mta.hu.

*E-mail: nicola.dellaca@unipr.it.

ORCID

Alessia Bacchi: 0000-0001-5675-9372

Raffaella Mancuso: 0000-0001-7514-6096

Bartolo Gabriele: 0000-0003-4582-1489

Raimondo Maggi: 0000-0003-3811-7186

Giovanni Maestri: 0000-0002-0244-8605

András Stirling: 0000-0002-1696-7932

Nicola Della Ca': 0000-0002-7853-7954

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We wish to thank the University of Parma and MIUR (Ministry of Education, University and Research, FFABR 2017) for financial support and CIM (Interdepartmental Measurements Centre) for the NMR facilities. Chiesi Farmaceutici SpA is acknowledged for the support with the D8 Venture X-ray equipment. We are thankful for the support from the COST (European Cooperation in Science and Technology) Action (CA15106) on C–H Activation in Organic Synthesis. A.S. acknowledges support from Grant K116034 of the NRDI Office, Hungary, and the computational resources of KIFÜ, Hungary.

■ REFERENCES

- (1) (a) Lee, K.-C.; Venkateswararao, E.; Sharma, V. K.; Jung, S.-H. Investigation of Amino Acid Conjugates of (S)-1-[1-(4-Aminobenzoyl)-2,3-Dihydro-1H-Indol-6-Sulfonyl]-4-Phenyl-Imidazolidin-2-One (DW2282) as Water Soluble Anticancer Prodrugs. *Eur. J. Med. Chem.* **2014**, *80*, 439–446. (b) Chang, C.-S.; Lin, Y.-T.; Shih, S.-R.; Lee, C.-C.; Lee, Y.-C.; Tai, C.-L.; Tseng, S.-N.; Chern, J.-H. Design, Synthesis, and Antipicornavirus Activity of 1-[5-(4-Arylphenoxy)-alkyl]-3-pyridin-4-ylimidazolidin-2-one Derivatives. *J. Med. Chem.* **2005**, *48*, 3522–3535. (c) Dage, R. C.; Roebel, L. E.; Gibson, J. P.; Okerholm, R. A.; Rolf, C. N. Enoximone. *Cardiovasc. Drug Rev.* **1986**, *4*, 63–79. (d) Reichard, G. A.; Stengone, C.; Paliwal, S.; Mergelsberg, I.; Majmundar, S.; Wang, C.; Tiberi, R.; McPhail, A. T.; Piwinski, J. J.; Shih, N.-Y. Asymmetric Synthesis of 4,4-Disubstituted-2-Imidazolidinones: Potent NK₁ Antagonists. *Org. Lett.* **2003**, *5*, 4249–4251. (e) Pettit, G. R.; McNulty, J.; Herald, D. L.; Doubek, D. L.; Chapuis, J.-C.; Schmidt, J. M.; Tackett, L. P.; Boyd, M. R. Antineoplastic Agents. 362. Isolation and X-Ray Crystal Structure of Dibromophakellstatin from the Indian Ocean Sponge *Phakellia Mauritanica*. *J. Nat. Prod.* **1997**, *60*, 180–183. (f) De Clercq, P. J. Biotin: A Timeless Challenge for Total Synthesis. *Chem. Rev.* **1997**, *97*, 1755–1792.
- (2) (a) Espinoza-Hicks, C.; Montoya, P.; Bautista, R.; Jiménez-Vázquez, H. A.; Rodríguez-Valdez, L. M.; Camacho-Dávila, A. A.; Cossío, F. P.; Delgado, F.; Tamariz, J. Synthesis of Exo-Imidazolidin-2-One Dienes, Their Isomerization, and Selectivity in Diels–Alder Cycloadditions. *J. Org. Chem.* **2018**, *83*, 5347–5364. (b) Koswatta, P.; Sivappa, R.; Dias, H.; Lovely, C. Total Synthesis of the Leucetta-Derived Alkaloid Calcaridine A. *Synthesis* **2009**, *2009*, 2970–2982. (c) Vasanthakumar, G. R.; Bhor, V. M.; Suroliya, A. Hydrolysis of Cyclic Ureas under Microwave Irradiation: Synthesis and Characterization of 7,8-Diaminopelargonic Acid. *Synth. Commun.* **2007**, *37*, 2633–2639. (d) Barrios Sosa, A. C.; Yakushijin, K.; Horne, D. A. Synthesis of Slagenins A, B, and C. *Org. Lett.* **2000**, *2*, 3443–3444.
- (3) (a) Lu, C.; Hu, L.; Yang, G.; Chen, Z. 2-Imidazolidinones as Chiral Auxiliaries in Asymmetric Synthesis. *Curr. Org. Chem.* **2012**, *16*, 2802–2817. (b) Guillena, G.; Nájera, C. (4R,5S)-1,5-Dimethyl-4-Phenylimidazolidin-2-One as a Chiral Auxiliary for the Diastereoselective Alkylation of a New Iminic Glycine Derivative: Practical Asymmetric Synthesis of α -Amino Acids. *Tetrahedron: Asymmetry* **1998**, *9*, 1125–1129. (c) Matsunaga, H.; Ishizuka, T.; Kunieda, T. Synthetic Utility of Five-Membered Heterocycles—Chiral Functionalization and Applications. *Tetrahedron* **2005**, *61*, 8073–8094.
- (4) (a) Casnati, A.; Motti, E.; Mancuso, R.; Gabriele, B.; Della Ca', N. Recent Advances in the Catalytic Synthesis of Imidazolidin-2-Ones and Benzimidazolidin-2-Ones. *Catalysts* **2019**, *9*, 28. (b) Sartori, G.; Maggi, R. In *Science of Synthesis (Houben–Weyl Methods of Molecular Transformations)*, Vol. 18; Ley, S. V., Knight, J. G., Eds.; Thieme: Stuttgart, 2005; pp 665–758. For selected examples on the use of CO as carbonylating agent, see: (c) Qian, F.; McCusker, J. E.; Zhang, Y.; Main, A. D.; Chlebowski, M.; Kokka, M.; McElwee-White, L. Catalytic Oxidative Carbonylation of Primary and Secondary Diamines to Cyclic Ureas. Optimization and Substituent Studies. *J. Org. Chem.* **2002**, *67*, 4086–4092. (d) Casiello, M.; Iannone, F.; Cotugno, P.; Monopoli, A.; Cioffi, N.; Ciminale, F.; Trzeciak, A. M.; Nacci, A. Copper(II)-Catalysed Oxidative Carbonylation of Aminols and Amines in Water: A Direct Access to Oxazolidinones, Ureas and Carbamates. *J. Mol. Catal. A: Chem.* **2015**, *407*, 8–14. (e) McCusker, J. E.; Grasso, C. A.; Main, A. D.; McElwee-White, L. Catalytic Oxidative Carbonylation of Primary and Secondary α,ω -Diamines to Cyclic Ureas. *Org. Lett.* **1999**, *1*, 961–964. (f) Gabriele, B.; Salerno, G.; Mancuso, R.; Costa, M. Efficient Synthesis of Ureas by Direct Palladium-Catalyzed Oxidative Carbonylation of Amines. *J. Org. Chem.* **2004**, *69*, 4741–4750. For a selected example on the use of dialkylcarbonates as carbonylating agents, see: (g) Ballini, R.; Fiorini, D.; Maggi, R.; Righi, P.; Sartori, G.; Sartori, R. TBD-Catalysed Solventless Synthesis of Symmetrically N,N'-Substituted Ureas from Primary Amines and Diethyl Carbonate. *Green Chem.* **2003**, *5*, 396–398. For a recent review and representative examples on the use of CO₂ as carbonylating agent, see: (h) Tamura, M.; Honda, M.;

Nakagawa, Y.; Tomishige, K. Direct Conversion of CO₂ with Diols, Aminoalcohols and Diamines to Cyclic Carbonates, Cyclic Carbamates and Cyclic Ureas Using Heterogeneous Catalysts: Direct Conversion of CO₂ with Diols. *J. Chem. Technol. Biotechnol.* **2014**, *89*, 19–33. (i) Yu, B.; Zhang, H.; Zhao, Y.; Chen, S.; Xu, J.; Hao, L.; Liu, Z. DBU-Based Ionic-Liquid-Catalyzed Carbonylation of *o*-Phenylenediamines with CO₂ to 2-Benzimidazolones under Solvent-Free Conditions. *ACS Catal.* **2013**, *3*, 2076–2082. (j) Kimura, T.; Kamata, K.; Mizuno, N. A Bifunctional Tungstate Catalyst for Chemical Fixation of CO₂ at Atmospheric Pressure. *Angew. Chem., Int. Ed.* **2012**, *51*, 6700–6703. (k) Tamura, M.; Noro, K.; Honda, M.; Nakagawa, Y.; Tomishige, K. Highly Efficient Synthesis of Cyclic Ureas from CO₂ and Diamines by a Pure CeO₂ Catalyst Using a 2-Propanol Solvent. *Green Chem.* **2013**, *15*, 1567–1577. (l) Paz, J.; Pérez-Balado, C.; Iglesias, B.; Muñoz, L. Carbon Dioxide as a Carbonylating Agent in the Synthesis of 2-Oxazolidinones, 2-Oxazinones, and Cyclic Ureas: Scope and Limitations. *J. Org. Chem.* **2010**, *75*, 3037–3046. (m) Wu, C.; Cheng, H.; Liu, R.; Wang, Q.; Hao, Y.; Yu, Y.; Zhao, F. Synthesis of Urea Derivatives from Amines and CO₂ in the Absence of Catalyst and Solvent. *Green Chem.* **2010**, *12*, 1811–1816. (n) Bhanage, B. M.; Fujita, S.; Ikushima, Y.; Arai, M. Synthesis of Cyclic Ureas and Urethanes from Alkylene Diamines and Amino Alcohols with Pressurized Carbon Dioxide in the Absence of Catalysts. *Green Chem.* **2003**, *5*, 340–342.

(5) (a) Zhu, Y.; Cornwall, R. G.; Du, H.; Zhao, B.; Shi, Y. Catalytic Diamination of Olefins via N–N Bond Activation. *Acc. Chem. Res.* **2014**, *47*, 3665–3678. (b) Zhu, Y.; Shi, Y. Cu^I-Catalyzed Sequential Diamination and Dehydrogenation of Terminal Olefins: A Facile Approach to Imidazolinones. *Chem. - Eur. J.* **2014**, *20*, 13901–13904.

(6) (a) Tabarki, M. A.; Besbes, R. Ring Expansion of Aziridine-2-Carboxylates. An Efficient Entry to Imidazolidin-2-Ones and Oxazolidin-2-Imines. *Tetrahedron Lett.* **2015**, *56*, 1837–1839. (b) Kennedy, M. D.; Bailey, S. J.; Wales, S. M.; Keller, P. A. Enantiopure *Trans* -4,5-Disubstituted 2-Imidazolidinones via Copper(I)-Catalyzed Ring Opening of 1,1'-DiBoc-2,2'-Biaziridine with Grignard Reagents. *J. Org. Chem.* **2015**, *80*, 5992–5998. (c) Xing, M.-L.; Lu, X.-W.; Miao, C.-B.; Li, J.-X.; Sun, X.-Q.; Yang, H.-T. Lewis Base-Catalyzed Reaction of Aziridinofullerene with Ureas for the Preparation of Fulleroimidazolidinones. *J. Org. Chem.* **2014**, *79*, 11774–11779.

(7) (a) Patel, M.; Saunthwal, R. K.; Verma, A. K. Base-Mediated Hydroamination of Alkynes. *Acc. Chem. Res.* **2017**, *50* (2), 240–254. (b) Yamamoto, C.; Hirano, K.; Miura, M. Cesium Hydroxide-Mediated Regio- and Stereoselective Hydroamidation of Internal Aryl Alkynes with Primary Amides. *Chem. Lett.* **2017**, *46*, 1048–1050. (c) Tzalis, D.; Knochel, P. Cesium Hydroxide: A Superior Base for the Catalytic Alkynylation of Aldehydes and Ketones and Catalytic Alkenylation of Nitriles. *Angew. Chem., Int. Ed.* **1999**, *38*, 1463–1465. (d) Tzalis, D.; Koradin, C.; Knochel, P. Cesium Hydroxide Catalyzed Addition of Alcohols and Amine Derivatives to Alkynes and Styrene. *Tetrahedron Lett.* **1999**, *40*, 6193–6195.

(8) For transition-metal-catalyzed intramolecular hydroamidation to five-membered cyclic ureas, see: (a) Huang, L.; Arndt, M.; Gooßen, K.; Heydt, H.; Gooßen, L. J. Late Transition Metal-Catalyzed Hydroamination and Hydroamidation. *Chem. Rev.* **2015**, *115*, 2596–2697. (b) Rajesh, M.; Puri, S.; Kant, R.; Sridhar Reddy, M. Ag-Catalyzed Intramolecular Sequential Vicinal Diamination of Alkynes with Isocyanates: Synthesis of Fused Indole-Cyclic Urea Derivatives. *J. Org. Chem.* **2017**, *82*, 5169–5177. (c) Pereshivko, O. P.; Peshkov, V. A.; Jacobs, J.; Meervelt, L. V.; Van der Eycken, E. V. Cationic Gold- and Silver-Catalyzed Cycloisomerizations of Propargylic Ureas: A Selective Entry to Oxazolidin-2-Imines and Imidazolidin-2-Ones. *Adv. Synth. Catal.* **2013**, *355*, 781–789. (d) Peshkov, V. A.; Pereshivko, O. P.; Sharma, S.; Meganathan, T.; Parmar, V. S.; Ermolat'ev, D. S.; Van der Eycken, E. V. Tetrasubstituted 2-Imidazolones via Ag(I)-Catalyzed Cycloisomerization of Propargylic Ureas. *J. Org. Chem.* **2011**, *76*, 5867–5872. (e) Lei, A.; Lu, X. Palladium(II)-Catalyzed Tandem Intramolecular Aminopalladation of Alkynes and Conjugate Addition. Synthesis of Oxazolidinones, Imidazolidinones, and

Lactams. *Org. Lett.* **2000**, *2*, 2699–2702. (f) Bacchi, A.; Chiusoli, G. P.; Costa, M.; Sani, C.; Gabriele, B.; Salerno, G. Nitrogen Heterocycles by Palladium-Catalyzed Oxidative Cyclization-Alkoxycarbonylation of Acetylenic Ureas. *J. Organomet. Chem.* **1998**, *562*, 35–43. (g) Fritz, J. A.; Nakhla, J. S.; Wolfe, J. P. A New Synthesis of Imidazolidin-2-Ones via Pd-Catalyzed Carboamination of *N*-Allylureas. *Org. Lett.* **2006**, *8*, 2531–2534. (h) Huang, S.; Shao, Y.; Liu, R.; Zhou, X. Facile Access to Oxazolidin-2-Imine, Thiazolidin-2-Imine and Imidazolidin-2-Imine Derivatives Bearing an Exocyclic Haloalkylene via Direct Halocyclization between Propargylamines, Heterocumulenes and I₂ (NBS). *Tetrahedron* **2015**, *71*, 4219–4226. (i) La-Venia, A.; Medran, N. S.; Krchňák, V.; Testero, S. A. Synthesis of a Small Library of Imidazolidin-2-Ones Using Gold Catalysis on Solid Phase. *ACS Comb. Sci.* **2016**, *18*, 482–489.

(9) For metal-free intramolecular hydroamidation to five-membered cyclic ureas, see: (a) Ranjan, A.; Yerande, R.; Wakchaure, P. B.; Yerande, S. G.; Dethe, D. H. Base-Mediated Hydroamination of Propargylamine: A Regioselective Intramolecular 5-*exo-dig* Cycloisomerization en Route to Imidazole-2-thione. *Org. Lett.* **2014**, *16*, 5788–5791. (b) Proulx, C.; Lubell, W. D. *N*-Amino-Imidazolin-2-One Peptide Mimic Synthesis and Conformational Analysis. *Org. Lett.* **2012**, *14*, 4552–4555. (c) Huguenot, F.; Delalande, C.; Vidal, M. Metal-Free 5-*Exo-Dig* Cyclization of Propargyl Urea Using TBAF. *Tetrahedron Lett.* **2014**, *55*, 4632–4635. (d) Liu, J.; Zhang, Y.; Li, G.; Roschangar, F.; Farina, V.; Senanayake, C. H.; Lu, B. Z. A Novel One-Pot, Two-Step Synthesis of Polycyclic Indoles via Tandem Intramolecular Hydroamidation/Palladium-Catalyzed Annulation. *Adv. Synth. Catal.* **2010**, *352*, 2667–2671. (e) Chiu, S. K.; Dube, M.; Keifer, L.; Szilagyi, S.; Timberlake, J. W. Attempted Synthesis of a Keto Diazene: Reactions of Propargylic Amines, Sulfamides, and Ureas. *J. Org. Chem.* **1978**, *43*, 61–65. (f) Easton, N. R.; Cassady, D. R.; Dillard, R. D. Reactions of Acetylenic Amines. VIII. Cyclization of Acetylenic Ureas. *J. Org. Chem.* **1964**, *29*, 1851–1855. (g) Stoffel, P. J.; Speziale, A. J. The Preparation of 2-Imidazolones: A Novel Ring Closure of Propynyl Ureas with Phosphorus Pentachloride. *J. Am. Chem. Soc.* **1962**, *84*, 501–502.

(10) (a) Khrakovsky, D. A.; Tao, C.; Johnson, M. W.; Thornbury, R. T.; Shevick, S. L.; Toste, F. D. Enantioselective, Stereodivergent Hydroazidation and Hydroamination of Allenes Catalyzed by Acyclic Diaminocarbene (ADC) Gold(I) Complexes. *Angew. Chem., Int. Ed.* **2016**, *55*, 6079–6083. (b) Kanno, O.; Kuriyama, W.; Wang, Z. J.; Toste, F. D. Regio- and Enantioselective Hydroamination of Dienes by Gold(I)/Menthol Cooperative Catalysis. *Angew. Chem., Int. Ed.* **2011**, *50*, 9919–9922. (c) Li, H.; Widenhofer, R. A. Gold(I)-Catalyzed Intramolecular Dihydroamination of Allenes with *NN'*-Disubstituted Ureas To Form Bicyclic Imidazolidin-2-ones. *Org. Lett.* **2009**, *11*, 2671–2674.

(11) Marchegiani, M.; Nodari, M.; Tansini, F.; Massera, C.; Mancuso, R.; Gabriele, B.; Costa, M.; Della Ca', N. Urea Derivatives from Carbon Dioxide and Amines by Guanidine Catalysis: Easy Access to Imidazolidin-2-ones under Solvent-Free Conditions. *J. CO₂ Utilization* **2017**, *21*, 553–561.

(12) Urea **1a** was prepared from 2-methylbut-3-yn-2-amine and phenyl isocyanate (see [Experimental Section](#) for details).

(13) (a) Taylor, J. E.; Bull, S. D.; Williams, J. M. J. Amidines, Isothioureas, and Guanidines as Nucleophilic Catalysts. *Chem. Soc. Rev.* **2012**, *41*, 2109–2121. (b) Coles, M. P. Bicyclic-Guanidines, -Guanidates and -Guanidinium Salts: Wide Ranging Applications from a Simple Family of Molecules. *Chem. Commun.* **2009**, 3659–3676.

(14) Kozell, V.; Rahmani, F.; Piematti, O.; Lanari, D.; Vaccaro, L. A. Stereoselective Organic Base-Catalyzed Protocol for Hydroamination of Alkynes under Solvent-Free Conditions. *Molecular Catalysis* **2018**, *455*, 188–191.

(15) CCDC 1876216 (**2a**), CCDC 1876217 (**2i**), CCDC 1876218 (**2n'**), CCDC 1876219 (**4c**), and CCDC 1876220 (**4j**) contain the supplementary crystallographic data for this paper. These data can be obtained free of charge from the Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.

(16) Frisch, M. J.; et al. *Gaussian 09*, revision A.02; Gaussian, Inc.: Wallingford, CT, 2009.

(17) Chai, J.-D.; Head-Gordon, M. Long-Range Corrected Hybrid Density Functionals with Damped Atom–Atom Dispersion Corrections. *Phys. Chem. Chem. Phys.* **2008**, *10*, 6615–6620.

(18) Predicted BTMG basicity was higher with respect to the others. For a similar overstabilization for BTMG, see: Turnell-Ritson, R. C.; Sapsford, J. S.; Cooper, R. T.; Lee, S. S.; Földes, T.; Hunt, P. A.; Pápai, I.; Ashley, A. E. Base-Induced Reversible H₂ Addition to a Single Sn(II) Centre. *Chem. Sci.* **2018**, *9*, 8716–8722.

(19) Ryde, U. A fundamental view of enthalpy–entropy compensation. *MedChemComm* **2014**, *5*, 1324–1336. Zhou, H.-X.; Gilson, M. K. Theory of Free Energy and Entropy in Noncovalent Binding. *Chem. Rev.* **2009**, *109*, 4092–4107.

(20) Ryu, H.; Park, J.; Kim, H. K.; Park, J. Y.; Kim, S.-T.; Baik, M.-H. Pitfalls in Computational Modeling of Chemical Reactions and How to Avoid Them. *Organometallics* **2018**, *37*, 3228–3239.

(21) Note that for clarity we indicated the level shifts only for the first two stages of the reactions although the next level is also shifted by the variation of the base. The initial and final states are not affected because the base is not protonated in these states (i.e., a spectator).

(22) *Modern Allene Chemistry*; Krause, N., Hashmi, A. S. K., Eds.; Wiley-VCH Verlag GmbH: Weinheim, Germany, 2004.

(23) For recent DFT studies carried out on catalytic sequences involving an allene group, see: (a) Cera, G.; Lanzi, M.; Balestri, D.; Della Ca', N.; Maggi, R.; Bigi, F.; Malacria, M.; Maestri, G. Synthesis of Carbolines via Palladium/Carboxylic Acid Joint Catalysis. *Org. Lett.* **2018**, *20*, 3220–3224. (b) Ocello, R.; De Nisi, A.; Jia, M.; Yang, Q.-Q.; Monari, M.; Giacinto, P.; Bottoni, A.; Miscione, G. P.; Bandini, M. Gold(I)-Catalyzed Dearomative [2 + 2]-Cycloaddition of Indoles with Activated Allenes: A Combined Experimental-Computational Study. *Chem. - Eur. J.* **2015**, *21*, 18445–18453.

(24) The DFT calculations also addressed the suppressed reactivity of **3q** (see SI for the details).

(25) Liu, J.; Shen, M.; Zhang, Y.; Li, G.; Khodabocus, A.; Rodriguez, S.; Qu, B.; Farina, V.; Senanayake, C. H.; Lu, B. Z. A New Entry to Polycyclic Indole Skeletons via Palladium-Catalyzed Intramolecular Heteroannulation. *Org. Lett.* **2006**, *8*, 3573–3575.

(26) Sonogashira, K.; Tohda, Y.; Hagihara, N. A Convenient Synthesis of Acetylenes: Catalytic Substitutions of Acetylenic Hydrogen with Bromoalkenes, Iodoarenes and Bromopyridines. *Tetrahedron Lett.* **1975**, *16*, 4467–4470.

(27) Brak, K.; Doyle, P. S.; McKerrow, J. H.; Ellman, J. A. Identification of a New Class of Nonpeptidic Inhibitors of Cruzain. *J. Am. Chem. Soc.* **2008**, *130*, 6404–6410.

(28) Yoo, W.; Li, C. Copper Catalyzed Four Component Coupling between Aldehydes, Amines, Alkynes, and Carbon Dioxide. *Adv. Synth. Catal.* **2008**, *350*, 1503–1506.

(29) Chang, Z.; Jing, X.; He, C.; Liu, X.; Duan, C. Silver Clusters as Robust Nodes and π -Activation Sites for the Construction of Heterogeneous Catalysts for the Cycloaddition of Propargylamines. *ACS Catal.* **2018**, *8*, 1384–1391.

(30) Mishra, P. K.; Verma, S.; Kumar, M.; Verma, A. K. Base-Mediated Direct Transformation of *N*-Propargylamines into 2,3,5-Trisubstituted 1*H*-Pyrroles. *Org. Lett.* **2018**, *20*, 7182–7185.

(31) Wang, H.; Ying, J.; Lai, M.; Qi, X.; Peng, J.-B.; Wu, X.-F. Base-Promoted Carbonylative Cyclization of Propargylic Amines with Selenium under CO Gas-Free Conditions. *Adv. Synth. Catal.* **2018**, *360*, 1693–1703.

(32) Shi, L.; Tu, Y.-Q.; Wang, M.; Zhang, F.-M.; Fan, C.-A. Microwave-Promoted Three-Component Coupling of Aldehyde, Alkyne, and Amine via C–H Activation Catalyzed by Copper in Water. *Org. Lett.* **2004**, *6*, 1001–1003.

(33) Bariwal, J. B.; Ermolat'ev, D. S.; VanderEycken, E. V. Efficient Microwave-Assisted Synthesis of Secondary Alkylpropargylamines by Using A³-Coupling with Primary Aliphatic Amines. *Chem. - Eur. J.* **2010**, *16*, 3281–3284.

(34) Ranjan, A.; Deore, A. S.; Yerande, S. G.; Dethe, D. H. Thiol-Yne Coupling of Propargylamine under Solvent-Free Conditions by

Bond Anion Relay Chemistry: An Efficient Synthesis of Thiazolidin-2-Ylideneamine. *Eur. J. Org. Chem.* **2017**, *2017*, 4130–4139.

(35) Pereshivko, O. P.; Peshkov, V. A.; Peshkov, A. A.; Jacobs, J.; Van Meervelt, L.; Van der Eycken, E. V. Unexpected Regio- and Chemoselectivity of Cationic Gold-Catalyzed Cycloisomerizations of Propargylureas: Access to Tetrasubstituted 3,4-Dihydropyrimidin-2(1*H*)-Ones. *Org. Biomol. Chem.* **2014**, *12*, 1741.